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CHAPTER 1. GENERAL INTRODUCTION 
Thesis organization 
 The following thesis consists of a general introduction in chapter 1, a literature review 
manuscript prepared for submission to Animal Health Research Reviews in chapter 2, a 
manuscript published in Veterinary Immunology and Immunopathology 102 (2004) 233–247 
in chapter 3, a manuscript prepared for submission to Vaccine in chapter 4, and general 
conclusions in chapter 5. All of the chapters contained within this thesis were written by 
Wesley Scott Johnson as primary author. 
Introduction 
 Porcine reproductive and respiratory syndrome virus is an enveloped single-stranded 
positive-sense RNA virus classified in the family Arteriviridae (Cavanagh 1997). Much of 
the research that has been done at both the genetic and protein levels for PRRSV has already 
been reviewed previously (Snijder and Meulenberg 1998; Dea, Gagnon et al. 2000), (Dea, 
Gagnon et al. 2000). Snijder et al. provided an early detailed description of the base 
knowledge known about the viral genome as well as the composition and function of the 
viral proteome. Porcine reproductive and respiratory syndrome virus encompasses a very 
diverse collection of isolates; even within its own genus, PRRS viruses possess great 
differences in their genomes and can be very different from one another at the individual 
isolate level with base changes, additions, or even deletions. When comparing nucleotide 
sequences of the VR-2332 and the LV isolates, very different sequences were seen with only 
about 61% identity in the 5’ leader sequence and only about 55% identity in the ORF1a 
region was observed (Nelsen, Murtaugh et al. 1999). Alternately, the ORF1b region was 
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found to be more similar between these same isolates with about 63% sequence identity, and 
75% amino acid identity. An earlier genomic comparison of the EU PRRSV LV isolate and 
the NA PRRSV VR-2332 isolate focusing on the viral envelope proteins ORF 5 and 6 found 
that sequence homology ranged from 55% in ORF5 to 79% in ORF6 (Murtaugh, Elam et al. 
1995). The fluidity of the PRRSV RNA genome and a lack of fidelity of the RNA dependant 
polymerase contributes to quasispecies where PRRSV exists not as a single isolate or even as 
a group of isolates, but more as a collection of very similar genotypes on a farm or even 
within a single animal (Goldberg, Lowe et al. 2003) (Rowland, Steffen et al. 1999). This 
characteristic of PRRSV produces genomic changes coding for changes within the PRRSV 
proteome, which in turn provides for the seemingly infinite diversity of the virus. There is no 
doubt that this diversity contributes to the challenge of vaccine development and PRRS 
control. 
 As implied by its name, the diseases caused by PRRSV infection can take two forms, 
each of which were thought to be separate multifactorial diseases before the etiologic agent 
was identified (Zimmerman, Yoon et al. 1997). The respiratory disease can be seen in all age 
groups of pigs and in some cases can be very severe, leading to death. The diversity in viral 
pathogenicity among PRRSV isolates has been reported by evaluating several different 
isolates each applied at a standardized dose (Johnson, Roof et al. 2004) and revealed that in 
vivo replication rate of the different PRRSV isolates was correlated to the level of 
pathogenesis within the host. The highly virulent isolates contributed to a 50% mortality rate 
in young pigs, while others that represented the more attenuated isolates did not induce 
clinical illness and were quickly cleared by the piglets. The reproductive disease can range 
from a lack of conception, early farrowing of congenitally-infected piglets with increased 
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mummies and dead born piglets, to abortion storms with significant piglet death loss and 
even sow death. The timing of sow infection has a great deal of influence on the severity and 
presentation of PRRSV-associated disease. When examining the reproductive disease around 
mid-gestation, time frame of 50 days or less, it was demonstrated that sows were susceptible 
to infection by intranasal exposure but their fetuses were for the most part not susceptible to 
viral infection through the placental barrier (Christianson, Choi et al. 1993). The study went 
on to show that direct infection in utero of the fetuses was possible within this same mid-
gestation time frame. Infection of a sow with PRRSV during late-gestation, the middle of the 
third trimester of pregnancy, was found to result in the congenital infection of the fetuses 
leading to increased fetal death and weak born piglets, followed by PRRSV transmission 
from the infected piglets to littermates before weaning (Mengeling, Lager et al. 1998).  
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CHAPTER 2. IMMUNIZATION STRATEGIES FOR PORCINE REPRODUCTIVE 
AND RESPIRATORY SYNDROME VIRUS 
 
A paper to be submitted to Animal Health Research Reviews 
Wesley Johnson 
Abstract 
This review is intended to discuss published work focused on the immunization of swine 
against porcine reproductive and respiratory syndrome virus (PRRSV). Many different 
strategies have been pursued by researchers in the quest for control and ultimately the 
eradication of porcine reproductive and respiratory syndrome (PRRS). Some of the strategies 
have lead to the licensure of commercial products while others have provided insight into the 
biology of PRRSV. Many of the strategies examined here have contributed to the overall 
understanding of the host’s immune response to PRRSV. Some strategies have provided 
unconventional or in some cases controversial methods of protecting swine from PRRS. The 
main area of interest in this review will be the clinical protection of swine from virulent 
PRRSV challenge. Gross lung pathology and viremia along with virus neutralizing antibody 
titers will serve as the primary parameters for protection in the respiratory challenge model, 
whereas the number of live born pigs and the number of weaned pigs along with piglet 
viremia will serve as the primary parameters for protection in the reproductive challenge 
model. Despite the incomplete reporting of these primary parameters, some publications will 
be discussed that have focused on protection against PRRSV by either evaluating the 
immune responses in non-target animals or studies conducted in swine, some without a 
virulent challenge. It is important to note that for the purposes of this review a homologous 
PRRSV challenge will be defined as a challenge with the same viral isolate from which the 
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vaccine was derived, and a heterologous PRRSV challenge will be defined as a challenge 
with a PRRSV isolate that is not the isolate from which the vaccine was derived. After 
evaluating the strategies based on these parameters the only immunization strategy that has 
provided efficacy against both a homologous and a heterologous challenge is the modified 
live vaccine.  
1. Introduction 
 Nearly 20 years after its characterization, Porcine Reproductive and Respiratory 
Syndrome (PRRS) is one of the most economically important diseases in the swine 
production industry. In the US, it was estimated in 2005, that the disease was responsible for 
over 66 million dollars of lost income from breeding animals and a loss of over 490 million 
dollars in growing-pig populations (Neumann, Kliebenstein et al. 2005). Retrospectively, 
porcine reproductive and respiratory syndrome virus (PRRSV) was first described in the 
swine populations of North America, but initially the disease was referred to as “mystery 
swine disease” (Hill 1990). The first PRRSV isolate to be well characterized was designated 
as the Lelystad (LV) isolate, which would later become the prototypical European (EU) 
PRRSV isolate, or type I PRRSV (Wensvoort, Terpstra et al. 1991). The reproductive disease 
observed in the case from which the virus originated was reproduced under controlled 
conditions, fulfilling Koch’s postulates that the LV EU PRRSV isolate was the cause of the 
clinical disease (Terpstra, Wensvoort et al. 1991). Soon after the discovery of PRRSV in 
Europe, a detailed description of both the growth properties and the viral structure was 
published for the isolate ATCC VR-2332, which was later considered the prototypical North 
American (NA) PRRSV isolate, or type II PRRSV (Benfield, Nelson et al. 1992). 
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  Porcine reproductive and respiratory syndrome virus is an enveloped single-stranded 
positive-sense RNA virus classified in the family Arteriviridae (Cavanagh 1997). Much of 
the research that has been done at both the genetic and protein levels for PRRSV has already 
been reviewed previously (Snijder and Meulenberg 1998; Dea, Gagnon et al. 2000), (Dea, 
Gagnon et al. 2000). Snijder et al. provided an early detailed description of the base 
knowledge known about the viral genome as well as the composition and function of the 
viral proteome. Porcine reproductive and respiratory syndrome virus encompasses a very 
diverse collection of isolates; even within its own genus, PRRS viruses possess great 
differences in their genomes and can be very different from one another at the individual 
isolate level with base changes, additions, or even deletions. When comparing nucleotide 
sequences of the VR-2332 and the LV isolates, very different sequences were seen with only 
about 61% identity in the 5’ leader sequence and only about 55% identity in the ORF1a 
region was observed (Nelsen, Murtaugh et al. 1999). Alternately, the ORF1b region was 
found to be more similar between these same isolates with about 63% sequence identity, and 
75% amino acid identity. An earlier genomic comparison of the EU PRRSV LV isolate and 
the NA PRRSV VR-2332 isolate focusing on the viral envelope proteins ORF 5 and 6 found 
that sequence homology ranged from 55% in ORF5 to 79% in ORF6 (Murtaugh, Elam et al. 
1995). The fluidity of the PRRSV RNA genome and a lack of fidelity of the RNA dependant 
polymerase contributes to quasispecies where PRRSV exists not as a single isolate or even as 
a group of isolates, but more as a collection of very similar genotypes on a farm or even 
within a single animal (Goldberg, Lowe et al. 2003) (Rowland, Steffen et al. 1999). This 
characteristic of PRRSV produces genomic changes coding for changes within the PRRSV 
proteome, which in turn provides for the seemingly infinite diversity of the virus. There is no 
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doubt that this diversity contributes to the challenge of vaccine development and PRRS 
control. 
 As implied by its name, the diseases caused by PRRSV infection can take two forms, 
each of which were thought to be separate multifactorial diseases before the etiologic agent 
was identified (Zimmerman, Yoon et al. 1997). The respiratory disease can be seen in all age 
groups of pigs and in some cases can be very severe, leading to death. The diversity in viral 
pathogenicity among PRRSV isolates has been reported by evaluating several different 
isolates each applied at a standardized dose (Johnson, Roof et al. 2004) and revealed that in 
vivo replication rate of the different PRRSV isolates was correlated to the level of 
pathogenesis within the host. The highly virulent isolates contributed to a 50% mortality rate 
in young pigs, while others that represented the more attenuated isolates did not induce 
clinical illness and were quickly cleared by the piglets. The reproductive disease can range 
from a lack of conception, early farrowing of congenitally-infected piglets with increased 
mummies and dead born piglets, to abortion storms with significant piglet death loss and 
even sow death. The timing of sow infection has a great deal of influence on the severity and 
presentation of PRRSV-associated disease. When examining the reproductive disease around 
mid-gestation, time frame of 50 days or less, it was demonstrated that sows were susceptible 
to infection by intranasal exposure but their fetuses were for the most part not susceptible to 
viral infection through the placental barrier (Christianson, Choi et al. 1993). The study went 
on to show that direct infection in utero of the fetuses was possible within this same mid-
gestation time frame. Infection of a sow with PRRSV during late-gestation, the middle of the 
third trimester of pregnancy, was found to result in the congenital infection of the fetuses 
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leading to increased fetal death and weak born piglets, followed by PRRSV transmission 
from the infected piglets to littermates before weaning (Mengeling, Lager et al. 1998).  
Many of the aspects associated with PRRSV transmission are well established and 
have been reviewed previously (Zimmerman, Yoon et al. 1997). More recent studies of 
PRRSV transmission have provided new insight into the complexity of virus transmission. 
The infectious-dose-fifty for the VR-2332 PRRSV isolate in three-week-old piglets was 
found to be about 2.0X105 virus particles by the oral route, but only about one twentieth that 
level, or 1.0X104 virus particles by the intranasal route (Hermann, Munoz-Zanzi et al. 2005). 
Although the study was only examined qualitatively, the shedding of PRRSV in mammary 
gland secretions has been observed. (Wagstrom, Chang et al. 2001). In another study the 
experimental spread of PRRSV via the airborne route from one pig unit to another was 
accomplished with controlled air exchange of as little as 1% of the total air intake 
(Kristensen, Botner et al. 2004). A later study found PRRSV to be present in just over 25% 
of oral and nasal swab samples collected from pigs experimentally inoculated with virulent 
PRRSV at three weeks of age, but the virus was not detected in aerosol samples from the 
same animals (Hermann, Brockmeier et al. 2008). The detection of PRRSV in oral fluids was 
examined, looking for either the virus or antibodies to the virus by using real time qRT-PCR 
or ELISA respectively, and found that PRRSV could be detected in the oral fluid by real time 
qRT-PCR for about four weeks after experimental inoculation (Prickett, Simer et al. 2008). 
The transmission of PRRSV was studied using persistently infected (PI) sows that were 
defined as such by a progression beyond acute disease after a wild-type viral exposure, but 
were found to be positive for PRRSV at necropsy (Bierk, Dee et al. 2001). Among other 
parameters, the absence of viremia by virus isolation helped define the end of acute disease at 
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42 days post exposure. PRRSV-naïve sows were then put into pens adjacent to the PI sows, 
allowing nose-to-nose contact and three out of four of the contact sows developed viremia 
and antibodies to PRRSV. It was confirmed that the virus obtained from the contact sows 
was the same as the wild-type isolate used during the exposure of the PI sows. Indicating that 
non-viremic PI sows, as defined in this study, were capable of transmitting PRRSV to naïve 
adjacently penned sows. 
 Porcine reproductive and respiratory syndrome virus immunology is very complex 
and an in-depth discussion will not be attempted here as several publications are available 
that can provide a more detailed perspective on PRRSV immunology. Briefly, PRRSV 
infects and replicates very efficiently in macrophages, which is thought to lead to both 
immunosuppression and predisposition to secondary infections (Molitor, Bautista et al. 
1997). The virus induces a weak interferon alpha response by the host, but there is some 
evidence of early innate immune responses with increases in NK cell numbers within five to 
seven days after infection (Murtaugh, Xiao et al. 2002). The virus is eventually cleared after 
a specific antibody and cell mediated response by the host to the virus. The initial antibody 
response by the host provides little aid in viral clearance but alternatively a virus neutralizing 
(VN) antibody response occurs and the virus is generally cleared (Lopez and Osorio 2004). 
Re-exposure of a host to PRRSV will generate a response that is generally protective for 
closely related viruses but less protective for viruses that are of the opposite type and thus 
considered heterologous to the vaccine isolate (Mateu and Diaz 2008). 
  Many different methods and combinations of methods have been used in an attempt 
to control PRRSV spread both on an individual farm and between different farms including 
depopulation, test and removal, and mass vaccination all of which are popular control 
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methods. For example, nursery depopulation was evaluated in an attempt to reduce the 
economic losses associated with PRRSV on 34 farms and it was determined that this method 
was a cost effective way of improving the profitability of PRRS-positive herds, especially if 
a producer had only limited capital, or could not use several sites to control the disease (Dee, 
Joo et al. 1997). Variations of the test and removal method have been employed by different 
producers with some success, using a systematic phased testing and culling of breeding 
stock, followed by testing and culling of nursery pigs (Yang, Moon et al. 2008), or testing of 
all animals on a single day then removing only the ones testing positive (Dee, Bierk et al. 
2001). The control of PRRSV within an entire region of France for several years was 
accomplished using a variation of the test and removal method, which completely 
depopulated whole farms that tested positive for PRRSV (Le Potier, Blanquefort et al. 1997). 
Combining methods such as pairing of the test and removal method for the elimination of 
persistently-infected breeding animals along with the depopulation method in the nursery and 
finisher facilities, allowed elimination of PRRSV from a test farm (Dee and Molitor 1998). 
By combining a breeding stock vaccination program with nursery depopulation, PRRSV was 
eliminated from a seedstock farm for 16 months after which the virus reappeared in only the 
finisher population (Dee, Joo et al. 1998).  
 The challenges associated with the development of a broadly effective and 
economical method to control PRRSV that can also be differentiated from a wild-type viral 
infection has fueled scientific interest in the characterization of PRRSV. The financial impact 
of the disease caused by PRRSV has also provoked the swine industry to push for more and 
better options in the control of PRRSV. With these motivators in place today, it is no surprise 
that the amount of research that has been done on PRRSV immunization is immense. An 
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important call for some much needed standardization of the protocols used by all researchers 
evaluating new PRRSV vaccine prototypes (Murtaugh, Dee et al. 2007) was again recently 
reiterated and explained further (Rowland 2008). Some of the strategies examined here have 
been discussed at a recent conference, but only in a very limited context and in reference to 
only a few specific studies (Roof 2008). The goal of this review is to provide a broad 
presentation of published work and the associated strategies used to immunize swine against 
PRRS. 
In the quest to address the question of how PRRSV can be controlled or eliminated 
there have been many strategies and ideas tested. The clinical protection of swine from 
virulent PRRSV challenge using a vaccination or immunization strategy will serve to focus 
the topics included in this review. Each section of the review will discuss a strategy in an 
attempt to categorize the published work, and provide an organizational framework of the 
ongoing efforts toward protection from PRRSV. The hope of the author is that the ultimate 
new PRRSV vaccine would be one that is very safe, broadly efficacious, easily differentiated 
from wild type exposure, and still economical for swine producers. A common theme 
repeated in this review is that each of the discussed strategies are missing at least one of the 
above attributes, that if were present would in turn identify the preferred strategy for vaccine 
development. 
2. PRRSV Passive Protection 
2.1 Background 
 Passive protection from disease is among the oldest strategies employed to protect a 
host from disease, but it can mean different things to different researchers. For the purposes 
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of this review, the term “passive protection” will be used in reference to the administration of 
a substance that is intended to provide protection from PRRSV by a means outside of 
invoking the host’s own immune system to provide the protection. The most common 
method for providing passive immunity for PRRSV is the parenteral administration of hyper-
immune serum to the susceptible host with the intent to confer protection from later or 
concurrent viral infection. Other forms of passive protection would include the transfer of 
maternal immunity through colostrum or the administration of antiviral compounds. 
2.2 Passive Protection from Respiratory Disease 
Protection of pigs from PRRSV viremia using intraperitoneally instilled passive 
immunity was shown to be dose dependant with serum virus neutralizing (VN) antibody 
titers of 1:8 being required for protection of piglets from viremia after a respiratory challenge 
(Lopez, Oliveira et al. 2007). INF-α was tested for its protective effects during PRRSV 
infection using a human adenovirus expressing porcine INF-α (Brockmeier, Lager et al. 
2009). The administration of the INF-α expressing adenovirus one day prior to a virulent 
PRRSV challenge provided for a decrease in the percent lung involvement and a delay in 
viremia when compared to the control group. A different approach to passive protection 
utilized an adenovirus that expressed small interfering RNAs targeted to the PRRSV ORF1b, 
ORF5 and ORF7 genes to suppress the viruses replication (Li, Jiang et al. 2009). The study 
was conducted in vitro so no conclusions on the protective efficacy of this approach can be 
made until a subsequent challenge study is conducted in swine. 
2.3 Passive Protection from Reproductive Disease 
By utilizing specific VN avian antibodies to a farm isolate of PRRSV, a somewhat 
unorthodox method of controlling PRRSV infection in a production setting was discovered in 
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central Mexico (Francos, Lucio et al. 2008). This new protection method was initiated by 
injecting all of the animals on the farm twice with the PRRSV specific VN avian antibodies 
about two weeks apart with the subsequent injection of sows between the 11th and 13th weeks 
of each gestation. In addition to sow treatments the piglets on the farm were also given the 
avian antibodies orally within the first 12 hours after birth. This use of passive protection was 
found to provide the farm with economic benefits by reducing both mortalities and the use of 
medication. The passive protection of pregnant animals from a virulent PRRSV reproductive 
challenge has been proven successful previously (Osorio, Galeota et al. 2002). In this study 
the administration of PRRSV-convalescent hyperimmune serum to sows on day 87 of 
gestation provided protection from an experimental virulent PRRSV challenge on day 90 of 
gestation. In a later study the challenge of either vaccinated or un-vaccinated gilts with 20 
different PRRSV field isolates showed that passive protection could be provided to piglets if 
the mother had been vaccinated prior to conception (Lager, Mengeling et al. 2003). However 
this protection was found to be incomplete, with two of the PRRSV isolates being found in 
the piglets from the vaccinated gilts. 
3. PRRSV Killed Virus Vaccination 
3.1 Background 
 Growing PRRSV in vitro or in vivo and inactivating it for use as a vaccine is one of 
the oldest strategies to be used when vaccinating pigs for the virus. Killed PRRSV 
vaccination is one of the two strategies that have lead to the development of commercially 
available vaccines. One of the fundamental benefits of a killed vaccine is its safety, with the 
virus being inactivated there is no chance for viral replication or vaccine shed, and thus no 
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chance for reversion or recombination to virulence. Another benefit to the use of killed 
vaccines is the fact that this type of vaccine can be quickly generated using the newest field 
isolates more quickly and safely than other strategies since these isolates will be inactivated 
in the final product. The use of killed PRRSV vaccines is not without challenges, for 
example, eliciting an immune response sufficient for protection by this method has proven 
difficult with the host’s antibody response not being detectable after the use of a killed 
vaccine. A vaccinated animal therefore is not readily differentiated from a naïve animal. It 
seems that for PRRSV there may be a fundamental tradeoff between safety and efficacy, 
because the same killed PRRSV vaccine that is completely safe seems to have little or no 
efficacy. 
3.2 North American PRRSV killed vaccines 
 There is only one killed NA PRRSV vaccine that has ever been licensed in the US 
(Vaccine A; table 1) and it is intended for use as a two-dose presentation in breeding age 
females, with two-dose boosters at each gestation. In the vaccine licensing trials (Vaccine A) 
provided for both a significant increase in the number of normal piglets and a significantly 
greater weight gain for those piglets born to vaccinated sows (Thacker, Thacker et al. 2003). 
In a later study it was determined through the vaccination (Vaccine A) of ten-week-old pigs 
that no decrease in the magnitude or duration of viremia was provided when comparing 
vaccinated and unvaccinated groups (Nilubol, Platt et al. 2004) (table 2). However, a 
significantly increased level of VN antibodies and a slightly increased number of INF-γ 
producing cells was observed in the vaccinated animals. The host’s reaction to vaccination 
was also studied by performing repeated vaccinations with either a killed vaccine (Vaccine 
A) or a licensed North American PRRSV modified live virus (MLV) vaccine (Vaccine B; 
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table 1) (Bassaganya-Riera, Thacker et al. 2004). This study found that regardless of the 
vaccine type used, repeated vaccination over an extended length of time resulted in a 
diminished immune responsiveness to specific PRRSV antigens.  
 Research has also been done looking at killed vaccines using North American isolates 
with a focus on protection from virulent PRRSV challenge with a very closely related isolate. 
For example, the vaccination of sows in China with a killed vaccine made from a virulent 
isolate provided for about 85% protection from a challenge with vaccine isolate while the 
immunity afforded to the unvaccinated piglets of vaccinated sows was found to provide 
about 92% protection from the same challenge (Cai, Guo et al. 2002) (table 2). Both of these 
levels of protection were based on reductions in the number of animals positive for live virus 
by isolation after the virulent challenge. An earlier study examining a killed autogenous 
vaccine showed that some protection was conferred to the vaccinated animals after a 
subsequent challenge with the same isolate used in the formulation of the vaccine (Osorio, 
Zuckermann et al. 1998) (table 3). However, the level of protection afforded by the killed 
vaccine was not as good as the protection provided by the modified live vaccines that were 
also examined in the study. 
3.3 EU PRRSV killed vaccines  
Killed PRRSV vaccines are marketed in the EU, with varying degrees of protection 
from various challenge isolates. The vaccination of either naïve or previously PRRSV-
exposed piglets with a commercially available killed EU PRRSV vaccine (Vaccine C; table 
1), lead to a significant reduction in the percentage of animals with viremia after a challenge 
with a homologous isolate (Reynaud, Charreyre et al. 2004) (table 2). A study evaluating 
INF-γ secreting T cell levels in pigs showed that vaccination (Vaccine C) could induce an 
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increase in the production of these cells soon after vaccination (Piras, Bollard et al. 2005) 
(table 2). Unfortunately, no post challenge clinical data were presented for this study, so a 
correlation between the increase in the INF-γ secreting T cells and clinical protection of the 
animals from disease could not be made. In a recently conducted study it was concluded that 
vaccination (Vaccine C) provided no protective immunity from a virulent LV challenge 
(Zuckermann, Garcia et al. 2007) (table 2). The effectiveness of a different EU PRRSV killed 
vaccine, Cyblue® (formally marketed by Cyanamid) had also been brought into question 
when it was tested in boars to determine if the level and duration of viremia could be reduced 
after a virulent challenge (Nielsen, Nielsen et al. 1997) (table 3). The vaccine was found to 
provide no reduction in the level or duration of viremia when compared to the challenge 
control boars. In a more recent vaccination (Vaccine C) study conducted in boars it was 
shown that there were no significant changes to the production of sperm or its quality, but 
without a virulent challenge in the study no conclusions could be made about the efficacy of 
the vaccine (Papatsiros, Alexopoulos et al. 2006). The vaccination (Vaccine C) of sows with 
in a field setting resulted in a significantly increased number of both live born and weaned 
pigs (Papatsiros, Koptopoulos et al. 2004) (table 3). After an extensive study evaluating the 
reproductive benefits provided by the extended use of vaccine (Vaccine C) in field exposed 
sows, it was determined that for the sow characteristics, only the premature farrowings were 
reduced in the four parities tested (Papatsiros, Alexopoulos et al. 2006). Also observed in this 
study, for reasons described as unclear by the authors, was a statically significant increase in 
the farrowing rate of the vaccinated group. As for the litter characteristics observed in this 
study, the number of weaned pigs was increased in vaccinated animals as compared to the 
unvaccinated animals. In order to evaluate its efficacy a study was conducted with a different 
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commercial EU PRRSV killed vaccine, Suvaxyn® PRRS (formerlly marketed by Fort Dodge 
Animal Health) (Scortti, Prieto et al. 2007) (table 3) and it was determined that the level of 
protection provided by the vaccine to a virulent reproductive challenge was nearly 
nonexistent, with the only statically significant difference between the challenge control 
animals and the vaccinated animals being the pre-weaning mortality of piglets, which was 
reduced in the vaccinated animals. 
 Other studies have been conducted using unlicensed killed PRRSV vaccine 
prototypes that were again based on EU isolates which have also shown varying degrees of 
protection from virulent challenge as well. A commercialized EU type PRRSV killed 
research prototype provided no protection to pigs after a subsequent respiratory PRRSV 
challenge with the virulent I2 isolate while an EU PRRSV MLV vaccine (Vaccine D; table 1) 
provided good protection from the same challenge (Gozio and Woensel 2006) (table 2). The 
vaccination of sows and gilts with an inactivated EU PRRSV vaccine containing an oil 
adjuvant resulted in a significant increase in both live born and weaned piglets after a field 
exposure of the animals to a wild type PRRSV isolate prevalent on the farm where the study 
was conducted (Reynaud, Brun et al. 2000). In an earlier study, the use of an inactivated EU 
type PRRSV vaccine containing an oil adjuvant that forms a double oil emulsion, also 
showed up to 80% protection of sows after a virulent reproductive challenge with the same 
PRRSV isolate used to generate the killed vaccine (Plana-Duran, Bastons et al. 1997). 
 The protective efficacy provided by killed PRRSV vaccination is questionable at best 
with nearly no protection seen after most respiratory evaluations and conflicting results in 
reproductive evaluations. Perhaps the future discovery of a unique immune response in the 
host after an exposure to replicating virus will provide some insight into the deficiencies in 
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the response after exposure to killed virus. This type of discovery could lead to some much 
needed improvements in killed PRRSV vaccines, but at this time killed vaccines do not 
provide adequate protection from PRRS. 
4. PRRSV Subunit Vaccination 
4.1 Background 
 The formulation of a prototype vaccine containing a single PRRSV protein, 
combinations of two or more proteins, fusions of whole viral proteins, or parts of viral 
proteins to either non-viral proteins or other carriers all describe PRRSV subunit vaccination. 
One of the biggest advantages of this strategy is its inherent ability to be used as a 
differentiating infected from vaccinated animals (DIVA) vaccine. This strategy has proven 
very effective for many other viral pathogens, usually ones that contain a single characterized 
antigen or group of antigens that have been shown to be protective when the immune 
response of the host is directed to them. With PRRSV being such a diverse group of viruses 
that have genomes predisposed to change and the fact that no definitive protective antigen is 
established for the virus, it is no surprise that this method of vaccination has shown only 
limited efficacy to date. 
4.2 Importance of and focus on the PRRSV Gp5 antigen 
 The consensus among many PRRSV researchers is that the viral Gp5 protein, 
encoded by the viruses ORF5 gene, plays a key roll in the interaction of the virus with the 
host cell, but a difference in the level of glycosylation of a glycoprotein could lead to 
differences in the interaction of antibodies with that protein. This idea has led to work 
focused on finding the neutralizing epitopes of Gp5 and also identifying VN monoclonal 
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antibodies (Mab’s) to the Gp5 protein. An in depth examination of the Gp5 ectodomain was 
performed using overlapping synthetic peptides to measure peptide-specific antibodies in 
experimentally infected pigs as well as field serum that showed VN antibodies (Plagemann 
2004). It was shown that antibodies to nine specific amino acids localized in the ectodomain 
of Gp5 were responsible for neutralization of the virus. Further testing was done looking at 
alteration of this peptide at specific amino acid positions and it was found that two regions 
consisting of three amino acids were required for neutralization of the virus. A more recent 
examination of the Gp5 protein was performed also using peptides, but focusing on 
immunodominant T-cell epitopes (Vashisht, Goldberg et al. 2008). Two of the 96 peptides 
tested were shown to have immunodominant T-cell epitopes and when the sequence of these 
two peptides from the isolate tested were compared to the sequences of other isolates it was 
found that there was a good level of homology with at most only two amino acid 
substitutions being observed. An evaluation of Mab’s to the Gp5 protein of a Canadian 
PRRSV isolate indicated that the Mab’s were in fact type specific because none of the Mab’s 
neutralized the EU LV PRRSV isolate and only two of the five Mab’s showed neutralization 
of the NA VR-2332 PRRSV isolate (Pirzadeh and Dea 1997). Further evaluation of several 
Mab’s directed at four PRRSV antigens, N, M, Gp5, and Gp3, showed that Mab’s directed to 
the N protein and portions of the Gp5 protein tended to cause antibody dependant 
enhancement while antibodies directed to the M, portions of the Gp5, and the Gp3 proteins 
showed VN properties (Cancel-Tirado, Evans et al. 2004). Interestingly, it was found that the 
Mab directed to the Gp3 (ISU45B) was statistically a much stronger inhibitor of viral 
replication in PAM cells than the Mab that recognized an epitope on the Gp5 protein 
(ISU25C).  
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4.3 Subunit vaccine prototypes for PRRSV 
 The hypothesis that Gp5 plays an important role in PRRSV infection of the host cell 
has lead to its use in several subunit vaccine prototypes, but Gp5 is not used exclusively. 
Other well-known PRRSV antigens as well as innovative new vaccine platform technologies 
are all currently being evaluated as vaccine prototypes. Purified Baculovirus expressed 
protein products of the PRRSV ORF5 and ORF3 genes were able to confer qualitative 
protection to sows as measured by an increased number of live born and weaned piglets as 
compared to the challenge control group (Plana Duran, Climent et al. 1997). It is important to 
note that the genes expressed by Baculovirus were originally cloned from same isolate that 
was used for the challenge in this study. The use of a PRRSV N protein fusion with 
Pseudomonas exotoxin provided partial protection from virulent challenge in piglets with a 
significant reduction in viremia, but once again no prevention of pneumonia (Liao, Lin et al. 
2004) (table 4). When fusion proteins consisting of PRRSV Gp5 and M fused to the 
Pseudomonas exotoxin were used to vaccinate piglets, the constructs again only provided 
partial protection from virulent challenge with microscopic lung lesions that were 
significantly decreased in the vaccinated animals but the reduction in viremia was only 
marginal and not significant (Liao, Yang et al. 2006) (table 4). The recent evaluation of 
fusion proteins consisting of PRRSV N and ORF1b to the Pseudomonas exotoxin provided 
only partial protection from virulent challenge in piglets with significant reductions in 
viremia, but not complete prevention of viremia (Liao, Weng et al. 2008) (table 4).  
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5. PRRSV DNA Vaccination 
5.1 Background 
 The reverse transcription of PRRSV RNA into cDNA followed with further genetic 
manipulations for use as a vaccine is one of the more modern strategies used in the 
vaccination of pigs for PRRSV. The strategy by design can be both safe and differentiated 
from a wild type exposure, but perhaps the biggest advantage to this strategy is that the fact 
that the host itself produces the viral proteins and the proteins are presented to the immune 
system in a manner similar to that during a natural infection. The drawbacks to this strategy 
are again a lack of sufficient protection, complexity, cost, and the labor involved in the 
vaccination process. DNA vaccines hold much potential for the future, but the current 
limitations of technology along with the complex immunology of PRRSV make this strategy 
difficult to commercialize at this time. 
5.2 Importance of and focus on the PRRSV ORF5 gene 
 Again, the focus for most PRRSV DNA vaccines has been put on the viral ORF5 
gene, either alone or in combination with other viral genes. An early pig challenge study 
evaluating a DNA vaccine that consisted of a plasmid with the PRRSV ORF5 under control 
of the cytomegalovirus (CMV) promoter was shown to induce a VN antibody titer sufficient 
for protection of the animals from a generalized viremia and macroscopic lung lesions 
following a challenge (Pirzadeh and Dea 1998) (table 4). A plasmid-based DNA vaccine 
coding for a fusion protein of PRRSV Gp5 to bovine herpes virus 1 VP22 was used to 
immunize mice which resulted in an increase in VN antibodies that was significantly greater 
than the increase seen in the group receiving the vaccine containing Gp5 alone (Zhao, Xiao et 
al. 2005). PRRSV DNA vaccination in piglets was tested using plasmids encoding the Gp5 or 
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M proteins either alone or in combination (Jiang, Xiao et al. 2006) (table 4). It was shown 
that VN antibodies could be detected within the animals by 10 weeks after the primary 
vaccination, but only in the combination group not in the groups given Gp5 or M alone. One 
of the conclusions of this study was that the heterodimer formed by the Gp5 and M proteins 
could in fact be an important antigen for developing a VN antibody response. Another DNA 
vaccination of mice with the PRRSV Gp5 gene, this time modified with a Pan DR T-helper 
cell epitope between the putative neutralizing epitope and a decoy epitope showed an 
enhanced level of VN antibodies when compared to the native Gp5 construct (Fang, Jiang et 
al. 2006). Very recently the PRRSV ORF5 gene was chosen for codon optimization and was 
used as a cDNA vaccine in a plasmid either with or without the addition of co-expressed 
swine ubiquitin (Hou, Chen et al. 2008) (table 4). The study found that the protection from 
virulent challenge was again only partial, even for the vaccine containing swine ubiquitin, 
which showed improved efficacy as compared to the other vaccines with a greater reduction 
of the viremia levels. The PRRSV Gp5 protein was once more the focus of a vaccine 
prototype, as a suicidal DNA vaccine expressing both a modified PRRSV Gp5 and the native 
PRRSV M proteins (Jiang, Fang et al. 2009) (table 4). In piglets the vaccine prototype 
elicited some protection from virulent PRRSV challenge, with a reduced incidence and 
duration of viremia as well as reductions in lung lesions. The vaccination of pigs with DNA 
vaccines encoding either ORF4, ORF5, ORF6, or ORF7 were able to elicit both a humoral 
and a cell mediated immune response (Kwang, Zuckermann et al. 1999) (table 4). The 
immune responses were measured by antibody production for the humoral and either 
interferon-gamma production or specific lymphocyte proliferation for the cell mediated 
response but since no virulent challenge was conducted the responses measured cannot be 
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correlated to protection. Vaccination of piglets with a DNA vaccine encoding a modified and 
mammalian codon optimized ORF5 gene from a highly virulent Chinese PRRSV isolate 
induced a significantly increased VN antibody response but again there was no virulent 
challenge of the pigs so no conclusions about protective efficacy can be made about this 
vaccine (Li, Xiao et al. 2009) (table 4).  
5.3 EU PRRSV DNA vaccine prototypes 
 Prototype DNA vaccines for PRRSV based on EU isolates have also been evaluated 
with much the same outcomes as those observed for the prototypes based on the NA isolates. 
A Danish PRRSV isolate was used to generate DNA vaccine constructs for each of the viral 
ORF’s including the ~11Kb ORF1a/b replicase, the constructs were then tested either 
individually or in combination (Barfoed, Blixenkrone-Moller et al. 2004) (table 4). After 
three vaccinations antibodies were readily detected in the ORF7 group, but only sporadically 
in the groups receiving the other ORF’s. After six vaccinations the pigs were challenged with 
the same PRRSV isolate used for the generation of the DNA vaccines, but the resulting 
disease remained sub-clinical even in the control animals. Measurement of antibodies 
specific to the Nsp2, Gp4, and Gp5 proteins indicated that a response was induced by the 
DNA vaccines containing the individual ORF’s and the vaccine consisting of the 
combination of all the ORF’s. A later study that focused on a EU type PRRSV ORF 7 DNA 
vaccine either alone or in combination with a porcine secondary lymphoid chemokine DNA 
vaccine was shown to elicit both a humoral and a cell mediated immune response, but these 
responses unfortunately did not confer protection (Diaz, Domínguez et al. 2006) (table 4). 
After challenge with the virulent isolate used to generate the DNA vaccines the typical 
PRRSV-induced growth retardation was observed along with viremia levels in the vaccinated 
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pigs that were similar to the levels in the challenge control pigs. The vaccination of pigs with 
EU PRRSV DNA vaccines encoding either the Gp4 or Gp5 proteins were again shown to be 
only partially protective (Ferrari, Petrini et al. 2006) (table 4). No measurable humoral 
response was seen in the vaccinated animals, but interestingly ther was a significant increase 
in the T-cell response observed in these same animals. Again the vaccines were unfortunately 
not able to prevent or even significantly reduce the levels or duration of viremia after a 
virulent PRRSV challenge with the same isolate used to generate the DNA vaccine. 
 Although much has been attempted using the DNA vaccine strategy for PRRSV 
immunization there are still many promising possibilities for future vaccine development. 
The advancements being made in the DNA vaccine industry bring this strategy closer to a 
reality each year. With many of the PRRSV DNA studies utilizing the CMV promoter, the 
evaluation of a more diverse array of promoters may be advised and will perhaps lead to a 
breakthrough in this vaccination strategy. 
6. PRRSV Vector Vaccination 
6.1 Background 
 The use of a genetically modified organism, which contains a PRRSV gene or group 
of genes, to vaccinate pigs to the virus is yet another strategy examined by researchers. The 
idea is that a replicating or non-replicating vector infects the host to facilitate the expression 
of the PRRSV genes. In some cases the vector itself is able to express the PRRSV genes 
outside of any assistance from the host while other vectors require assistance from the host to 
express the proteins of interest. The two major advantages of this strategy are again the safety 
of the vector and its inherent ability to be differentiated from a wild type exposure. The 
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drawbacks of vector vaccination include the hosts’ immune response specific to the vector, 
which makes subsequent vaccinations difficult, and much like the other strategies discussed 
earlier, the lack of sufficient efficacy remains a problem. The availability of a universally 
protective PRRSV antigen that could be expressed in a vector system would illustrate the 
potential usefulness of this strategy. 
6.2 Bacterial vectors 
Live vector vaccines have been developed for PRRSV utilizing different bacterial 
species. A recombinant Mycobacterium bovis BCG (BCG) was generated that expressed a 
truncated PRRSV Gp5 and the entire PRRSV M protein (Bastos, Dellagostin et al. 2002). 
The proteins were expressed so as to allow for localization to either the cytoplasm or surface 
of the BCG. These BCG constructs were tested in mice resulting in the induction of 
antibodies to the viral proteins detected by both ELISA and Western blot. A later study of the 
same BCG vector vaccine in pigs found only partial protection from virulent challenge with a 
reduction in viremia, pyrexia, and viral load in bronchial lymph nodes but no prevention of 
these parameters (Bastos, Dellagostin et al. 2004) (table 4). Mice were immunized with 
attenuated live Salmonella typhimurium aroA isolate which was transformed with a PRRSV 
Gp5 DNA vaccine vector (Jiang, Jiang et al. 2004). The same level of VN antibody titer was 
seen with this vector vaccine as were seen with the naked plasmid DNA vaccine, but if the 
neutralizing epitope was removed from the Gp5 within either of the vaccines it was found 
that the levels of VN antibody titer were significantly reduced. It is important to note that 
although good expression of the desired viral protein is often achieved when using 
prokaryotic expression vectors the antigen generated will be free of any glycosylation, which 
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could present problems in antigenic recognition by the host’s immune system when it is 
exposed to PRRSV.  
6.3 Pseudorabies virus vectors 
 Pseudorabies virus (PRV) is one of the more widely utilized live viral vectors 
developed for PRRSV vaccines and has shown varying degrees of protection from challenge. 
A recombinant PRV vaccine expressing the PRRSV Gp5 was evaluated in the piglet 
respiratory model and was shown to provide no protection from a virulent EU PRRSV 
challenge as indicated by the levels of viremia post challenge (Álvarez, Prieto et al. 2004) 
(table 4). Another evaluation of a recombinant PRV that expressed the PRRSV Gp5 protein 
that again was evaluated in the piglet respiratory model, only this time along side the parent 
PRV vaccine and a killed PRRSV vaccine (Qiu, Tian et al. 2005) (table 4). The results of the 
study indicated that the recombinant PRV vaccine expressing PRRSV Gp5 provided the best 
level of protection from virulent challenge with no clinical signs of disease, viremia for only 
two weeks, and only mild lung lesions in the animals receiving the vaccine. A later study of 
recombinant pseudorabies viruses was designed to evaluate, in mice, prototypes that were 
generated to express the PRRSV Gp5 or M proteins individually or in combination, as either 
native or modified proteins (Jiang, Fang et al. 2007) (table 4). The vector that elicited the 
greatest immune response in mice was found to be the one expressing the combination of 
both the modified Gp5 protein and the native M protein. This vector was then further tested 
in pigs for its ability to provide protection from a virulent PRRSV challenge and was shown 
to provide some protection from challenge, as indicated by a reduced level of lung lesions 
and a shorter duration of viremia when compared to a commercially available killed vaccine 
that was included in the study as a control.  
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6.4 Adenovirus vectors 
 Adenoviruses have been used for the development of promising viral vectors for 
PRRSV vaccination. Recombinant adenoviruses expressing the PRRSV Gp5 and M proteins 
individually or in combination were tested in mice to determine the immunological responses 
elicited to each (Jiang, Jiang et al. 2006). The virus co-expressing the Gp5 and M proteins 
provided a superior response, as indicated by significantly higher VN antibody titers and 
stronger lymphocyte proliferation responses. Again, adenoviruses were evaluated in mice for 
immunogenicity, one vector expressed the whole Gp3 protein and the other vector expressed 
a truncated version of Gp3 referred to as modified Gp3 (Jiang, Jiang et al. 2007). The vector 
expressing the modified Gp3 was found to provide a significantly enhanced immune 
response when compared to vector with the unmodified Gp3. In a very recent study the 
expression by adenovirus of Gp3, Gp4, and Gp5 gene fusions of varying combinations in 
mice were evaluated for both VN antibody production and cell-mediated immune responses 
(Jiang, Jiang et al. 2008). These responses were shown to be significantly enhanced when the 
fusions were compared to the viral vectors containing only the individual genes. 
Adenoviruses that expressed both the PRRSV Gp3 and Gp5 proteins each fused to the 
Haemophilus parasuis heat shock protein 70 (HSP70) with different linkers were shown to 
provide partial protection to pigs after being challenged with the same PRRSV isolate used to 
generate the recombinant vector vaccine (Li, Jiang et al. 2009). The protection of the 
vaccinated animals was measured by a reduction in, but not the prevention of clinical signs, 
lung lesions, and viremia when compared to the unvaccinated challenged animals. In a recent 
study adenoviruses expressing either PRRSV Gp3 and Gp5 alone or with co-expressed swine 
granulocyte-macrophage colony stimulating factor (GM-CSF) were evaluated for protection 
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from challenge with the isolate which the Gp3 and Gp5 genes originated from (Wang, Li et 
al. 2009) (table 4). The level of protection was superior in the group co-expressing PRRSV 
Gp3, Gp5, and the GM-CSF, with significantly decreased lung lesions and clinical signs. 
6.5 Other viral vectors  
Several other viral vectors have been used as prototype vector vaccines for PRRSV. 
For example, a recombinant vaccinia virus expressing the PRRSV ORF2 gene was used to 
vaccinate piglets, resulting in the production of a significant VN antibody titer (Rogan, 
Levere et al. 2000) (table 4). The utility of different recombinant modified vaccinia virus 
constructs expressing the Gp5 and M PRRSV proteins in different arrangements were 
evaluated through immunizing mice (Zheng, Chen et al. 2007). The vector that expressed the 
two proteins separately each controled by a different promoter resulted in the greatest VN 
antibody response and cellular immune response. A transmissible gastroenteritis coronavirus 
(TGEV) minigenome that expressed PRRSV ORF5 was used to vaccinate pigs resulting in 
the detection of a humoral immune response in the vaccinated animals (Alonso, Sola et al. 
2002) (table 4). Some of the early investigations of the PRRSV LV isolates’ proteins were 
performed using the semliki forest virus (SFV) expression system (Meulenberg and Petersen-
den Besten 1996), (Meulenberg, van Nieuwstadt et al. 1997). More recently the SFV 
expression system was evaluated for PRRSV ORF5 antigen production with aspirations of 
using the recombinant virus particles in a vaccine prototype (Jung, Hwang et al. 2002). 
Recombinant fowlpox viruses co-expressing the PRRSV Gp3 and Gp5 proteins either with or 
without porcine IL-18 provided some protection after a virulent PRRSV challenge with the 
same isolate used to generate the recombinant vector vaccine (Shen, Jin et al. 2007) (table 4). 
This protection was illustrated by a reduction in viremia and fewer virus isolations from the 
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bronchial lymph nodes in the vaccinated animals when compared to the control animals. A 
modified recombinant Baculovirus gene delivery vector expressing both the PRRSV Gp5 and 
M proteins under the control of independent CMV immediate early promoters was used to 
vaccinate mice (Wang, Fang et al. 2007). With a significantly enhanced production of VN 
antibodies and a significantly increased level of INF-γ this vaccination study showed that the 
vector, even at its lowest dose, was able to outperform a DNA vaccine encoding the same 
antigens. A recent study of killed TGEV vector prototype vaccine expressing the PRRSV 
ORF5 and ORF6 gene products was able to induce only partial protection from challenge as 
illustrated by reduced viremia and faster antibody production in the vaccinated animals, but 
interstitial pneumonia was still detected in the vaccinated animals (Urniza, Ceriani et al. 
2008) (table 4). New approaches to the creation of DIVA PRRSV vector vaccines are 
currently being developed by Sirrah Bios in collaboration with AlphaVax (Harris, Erdman et 
al. 2008). A whole new PRRSV vaccine platform is being generated, consisting of virus like 
replicon particles that can be used to immunize swine to PRRSV. This new approach to the 
vector vaccination strategy has been shown to provide partial protection to pigs from a 
virulent respiratory PRRSV challenge (Mogler, Erdman et al. 2008). 
Although promising data exists for this strategy, much of it has been generated in the 
mouse model focusing primarily on immunological parameters. More studies need to be 
conducted in swine that incorporate virulent challenges before a true understanding of the 
full potential afforded by vector vaccination against PRRSV can be realized. 
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7. PRRSV Infectious Clone Vaccination 
7.1 Background 
 Using infectious clones of PRRSV for MLV vaccine prototypes is again a potential 
strategy for vaccine development. The strategy consists of producing a cDNA construct of 
the entire viral genome, which can then be genetically manipulated more easily than the 
RNA genome of the virus. In order to incorporate attenuating changes into the new cDNA 
clone, bases can be changed, deleted, or exchanged with other clones either systematically or 
randomly. Infectious PRRSV cDNA clone vaccines again have the potential advantage of 
being differentiated from wild-type-exposed animals and also the potential to be safe. This 
strategy is not without risk as it does come with some disadvantages, such as the potential for 
reversion or recombination to virulence. Porcine reproductive and respiratory syndrome virus 
infectious cDNA clone work has been done using both single isolate infectious clones and 
multi-virus chimera clones. The work done with PRRSV infectious clones contributes to the 
body of knowledge that already exists for Equine Arteritis Virus (EAV) and Poliovirus 
infectious clones and adds to the understanding of the host’s immune response to the viral 
infection as well as providing some insight into the functions of the different viral proteins 
that are encoded by the compact but very complex PRRSV genome (Yoo, Welch et al. 2004).  
 The first ever cDNA infectious clone made for any PRRSV isolate was based on the 
LV isolate and incorporated mutations that added a unique PacI restriction site directly 
following the ORF7 gene (Meulenberg, Bos-de Ruijter et al. 1998). These mutations were 
found to be present in the virus that was rescued after an RNA transfection of BHK-21 cells 
and subsequent passage in PAM cells or CL2621 cells. The presence of the unique PacI site 
in the progeny virus supports the fact that this virus was in fact generated de novo from the 
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cloned cDNA. The first cDNA infectious clone that was generated for a NA PRRSV isolate 
was based on the prototypical VR-2332 isolate (Nielsen, Liu et al. 2003). This clone 
incorporated several genetic changes when compared back to the parent isolate two of which 
affected amino acid sequence. It was shown that besides a slightly lower titer when grown in 
Marc-145 cells the cDNA clone behaved the same as the parent isolate. In fact, when this 
clone was tested in 5.5-week-old pigs it displayed the same clinical signs as the parent virus 
right down to the observation of the characteristic blue colored ears on the challenged 
animals. 
7.2 Infectious clones for evaluating PRRSV biology 
 The utilization of PRRSV cDNA clones makes genetic manipulation of the virus 
much less cumbersome and thus has enabled a new era of research into the biology of 
PRRSV. For example, reverse genetics were used to manipulate a cDNA clone of PRRSV to 
produce separate PRRSV mutants each with one of the cysteines within the N protein 
substituted with a serine (Lee, Calvert et al. 2005). These manipulations were done in order 
to examine the ability of the virus to replicate when key dimmer sites were removed from the 
protein. The removal of either of two out of the three cysteine amino acids resulted in a lethal 
phenotype for the virus, but since cysteine 23 is known to form a covalently bonded 
homodimmer it was expected that changing it would result in the loss of replication of the 
virus. Interestingly though, cysteine 90 was not known to be involved with any dimmer 
formation so when changing it resulted in the loss of viral replication it was hypothesized 
that this residue could possibly be involved in the formation of a dimmer as well. Recently 
PRRSV cDNA clones were generated based on a Chinese isolate that is thought to be 
responsible for the production of a specific set of clinical signs characterized as porcine high 
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fever syndrome (PHFS) (Lv, Zhang et al. 2008). The overall goal of this work was to 
unequivocally identify PRRSV as the causative agent behind PHFS and in fact this was 
accomplished through the fulfillment of Koch’s postulates using the characterized cDNA 
clone of the PRRSV isolate. In an early infectious clone study, PRRSV was explored as a 
possible vector to carry small fragments of genetic information encoding peptides from other 
pathogens like Influenza as a proof of concept (Groot Bramel-Verheije, Rottier et al. 2000). 
The PRRSV clone which has an A2 autoprotease site added to remove the peptide from the N 
protein was shown in fact to be able to not only continue its replication and function in 
cultured alveolar macrophages but it was also shown to efficiently express the added genetic 
material encoding the nine Influenza amino acids. A study to determine if the EU PRRSV 
Gp5/M protein heterodimmer was responsible for the virus’s cell tropism was designed 
where by the ectodomain of the M protein was substituted with that of several other viruses 
including the NA PRRSV VR-2332 isolate and EAV (Verheije, Welting et al. 2002). The 
changes in the ectodomain of the M protein tested in this study had no influence on the 
virus’s cell tropism, indicating that the M protein within the Gp5/M protein heterodimer may 
not be involved in cell tropism. Very recently a cDNA clone of the APRRS isolate was 
mutated in order to separate the individual coding regions of the virus and to provide for 
more straight forward manipulations in generating chimeric viruses (Yuan and Wei 2008). 
This manipulation of the cDNA clone could possibly provide the building blocks needed for 
generating a better and more cross protective PRRSV vaccine. 
7.3 Comparisons of infectious clones to their parental isolates 
 Much of the research into infectious clone vaccination involves the comparison of the 
parent PRRSV isolate to its cDNA clone with respect to in vitro and in some cases in vivo 
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characteristics. The generation of a cDNA clone that was able to replicate both in vitro and in 
vivo to levels equivalent to its parent isolate, provided a starting point for the evaluation of 
the attenuation level of vaccine candidates generated by incorporating mutations into the 
clone (Truong, Lu et al. 2004). Two other infectious PRRSV cDNA clones, one virulent and 
one vaccine-derived were evaluated to examine the phenotypes of the clones both in vitro 
and in vivo (Kwon, Ansari et al. 2006). The results indicated that the vaccine-derived 
infectious clone retained the attenuated phenotype of its parental isolate, and the wild type 
clone retained the virulent phenotype of its parental isolate. The Nsp2 region of the PRRSV 
genome was evaluated recently using a cDNA clone to determine if it was possible for the 
virus to accommodate the deletion of specific parts of the Nsp2 gene (Ran, Chen et al. 2008). 
The virus was in fact able to replicate faster in vitro after the deletion, indicating that the 
deleted portions of the gene were not essential for viral growth in cell culture. 
7.4 Infectious clone vaccinations 
 Full-length cDNA constructs of PRRSV isolates are not only useful for basic research 
of the biology of PRRSV, they have in fact also been designed and used as vaccine 
prototypes that have been evaluated directly (without modification from the parent virus), as 
genetically modified versions of the parent isolate, and as chimera viruses made of more then 
one PRRSV isolate. Three different PRRSV cDNA clones each based on the LV isolate were 
evaluated for safety as well as efficacy from challenge with either homologous (EU PRRSV) 
or heterologous (NA PRRSV) isolates (Verheije, Kroese et al. 2003) (table 4). Because the 
parental isolate of the cDNA clones was not considered to be virulent the stability of the 
mutations that were incorporated into the clone served as a standard to evaluate safety. The 
mutations incorporated into the cDNA clones included both nucleotide deletions and 
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nucleotide substitutions. In eight-week-old pigs, the changes to the cDNA clones remained 
stable throughout the in vivo test period even while the animals developed viremia, indicating 
that the cDNA clones were stable and viable. The efficacy of the cDNA clones to a 
homologous challenge was good with only one pig from each of two of the cDNA vaccinated 
groups showing viremia post challenge. Unfortunately, the efficacy of the cDNA clones to 
heterologous challenge was poor with viremia in all of the vaccinated animals that were 
challenged, but on a more positive note, no viremia was seen in the vaccinated sentinels that 
were added to two of the challenged groups. In another study, two different cDNA clones 
that were constructed based on the PRRSV isolate P129 genome and with deleted ORF2 or 
ORF4 genes, respectively, were evaluated for safety and efficacy (Welch, Jolie et al. 2004) 
(table 4). The PRRSV deletion clones were shown to be stable in cell lines complementing 
the deleted genes, but offered no protection in vaccinated pigs from a challenge with the 
same isolate used to construct the cDNA clones and it was evident that the limited-replicating 
cDNA clones would not make good vaccines. Even though the clones were not efficacious, 
they could still serve as useful tools for investigating the function of the respective protein 
encoded by the deleted genes leading to a better understanding of the overall biology of 
PRRSV. The manipulation of two different cDNA clones, one generated from a vaccine 
isolate (Vaccine B) and one from a virulent field isolate (MN184), resulted in the 
development of several PRRSV chimera clones (Wang, Liang et al. 2008) (table 4). These 
chimera virus clones represented combinations of the genes encoding the structural proteins 
(ORF2-7) of one virus and the genes encoding the replication proteins (ORF1a/b) of the other 
virus. When evaluated in vivo the chimera viruses were attenuated as compared to the 
MN184 isolate cDNA clone but not to the attenuation level of the vaccine (Vaccine B) 
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cDNA clone. In evaluating their pathogenicity, lung scores in the chimera clone groups were 
observed to be intermediate to the almost absent scores seen in the animals inoculated with 
the vaccine (Vaccine B) cDNA clone and the high scores of over 40% seen in the animals 
inoculated with the MN184 cDNA clone. Another study of PRRSV cDNA chimera clones 
involved the generation of individual chimera clones using the genetic backbone of a virulent 
virus and the individual structural proteins of a vaccine isolate, in addition a cDNA clone 
utilizing the ORF5 of a second virulent virus was also incorporated into this same genetic 
backbone (Kwon, Ansari et al. 2008). The goal of this research was to determine the possible 
role of each of the structural genes in the attenuation process of the virus. Safety testing in 
the reproductive model, found that the ORF5 structural gene provided the most significant 
level of attenuation, followed by the ORF2 gene and then the remaining genes were found 
not to contribute to the virulence of the virus, but as a safety study with no virulent challenge 
of the animals no conclusions as to the efficacy of these vaccines could be made. 
A PRRSV DIVA vaccine clone was created by incorporating deletions in the Nsp2 
region of the viral genome (de Lima, Kwon et al. 2008). Specific B-cell epitopes within the 
Nsp2 region were targeted for deletion so as to obtain a unique serological response in the 
vaccinated animals, which would be easily detected via ELISA. Differentiation of animals 
infected with the wild type virus from those vaccinated with the deletion mutant proved to be 
successful, by using the commercially available IDEXX PRRSV ELISA kit for the detection 
antibodies to the PRRSV N protein, and an ELISA specifically developed to detect 
antibodies directed to the deleted portion of the Nsp2 gene, but because there was no 
challenge there is no efficacy data available for this study. Other efforts to investigate a 
DIVA incorporated differentiating attributes by utilization of deletions in the Nsp2 gene, but 
37 
in this study the Green Florescent Protein gene was added to the PRRSV cDNA clone in 
place of the deletion (Fang, Rowland et al. 2006). The cDNA clone was subsequently used as 
a vaccine allowing vaccinated animals to be differentiated from those exposed to wild type 
virus using an ELISA, unfortunately once again no data on protection was presented for this 
study, as there was no challenge (Fang, Christopher-Hennings et al. 2008). The insertion of 
the new genetic material into the PRRSV genome proved to again demonstrate the lack of 
genomic stability in the virus through the mutation of the GFP and its loss of florescence. 
Other groups have also focused on the Nsp2 gene, using cDNA clones with even larger 
deletions to produce marker vaccine clones, which also resulted in the easy differentiation of 
vaccine and wild-type-exposed animals by serology using an ELISA or molecularly using 
RT-PCR, but again no data was presented for efficacy, because there was no challenge in the 
study (Kim, Kaiser et al. 2009).  
8. PRRSV Modified Live Virus Vaccination  
8.1 Background 
The use of a PRRSV modified live virus (MLV) vaccine is a common commercial 
strategy used in vaccination of swine to protect against PRRSV. This strategy has been 
employed to generate licensed and commercially available PRRSV vaccines, several of 
which are still being sold today (Vaccine B, Vaccine D, Vaccine E; table 1, and Vaccine F; 
table 1). The details of the processes employed for generating an MLV vaccine vary, but they 
generally involve the sequential passage of the virus isolate of interest in a cell line 
permissive to its replication until it is sufficiently attenuated to the point of not causing 
clinical disease in the host. The major advantage to this strategy is that it provides an 
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infectious virion that stimulates an appropriate immune response similar to the response seen 
after a wild type infection. This advantage of PRRSV MLV vaccines is likely due to the fact 
that the vaccine isolates are genetically very similar to the virulent parent isolates. A 
complete genome comparison between the PRRSV isolate VR-2332 and its attenuated 
vaccine isolate (Vaccine B) showed that only 41 nucleotides were changed in the attenuation 
process of the virus (Yuan, Mickelson et al. 2001). Of those mutations, ten were silent when 
looking at the resulting amino acids and an additional five mutations were considered to be 
conservative changes. This led to an untested theory that the remaining twenty-six mutations 
provided the attenuated phenotype of the vaccine isolate. Since MLV vaccines became 
available many different combinations of both herd management practices and vaccination 
protocols have been successfully established for the proper use of the MLV vaccines against 
PRRSV in the field (Dee, Joo et al. 1998), (Philips and Dee 2002), (Gillespie 2003), 
(Gillespie and Carroll 2003), (Wetzell 2004), (Eger 2000), (Philips, Jordan et al. 2000), 
(Beilage and Beilage 2004), (Angulo, Diaz et al. 2006), and (Lebret and Ridremont 2008). 
Some drawbacks do still exist for the use of MLV vaccines and include the lack of 
differentiation from a wild type exposure, and there is a potential for reversion of the MLV to 
a more virulent form. 
8.2 Laboratory respiratory efficacy 
In the swine industry the PRRSV MLV vaccine is a common option for vaccination. 
A summary of 16 controlled lab scale PRRSV MLV vaccination studies each including a 
virulent challenge provided the collective conclusion that the use of NA PRRSV MLV 
vaccines (Vaccine B or Vaccine F) significantly reduced the appearance of lung lesions after 
each challenge, regardless of what challenge isolate was used (Roof 2008). Furthermore, in a 
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side by side comparison a killed NA PRRSV vaccine (Vaccine A) was unable to induce VN 
antibodies to PRRSV while the use of either wild type PRRSV exposure or MLV PRRSV 
vaccine (Vaccine B) to immunize animals resulted in the induction of a VN response (Meier, 
Galeota et al. 2003). It was noted that this VN response was however delayed when 
compared to the overall antibody response of the host. Pigs were protected from a challenge 
with either of two different virulent Japanese PRRSV isolates after being vaccinated 
(Vaccine B) (Okuda, Kuroda et al. 2008) (table 5). It was determined that this vaccine 
provided a greater weight gain and reduced both lung lesions and clinical signs after the 
challenge with either of the isolates. As might be expected pigs challenged with the PRRSV 
isolate that shared more similarity with the vaccine isolate showed a reduction in virus 
isolation from serum, bronchoalveolar lavage fluid, and tissues while no reductions were 
seen for these same parameters in the animals challenged with the more genetically unrelated 
isolate. Other researchers have shown that high passage of PRRSV field isolates in cell 
culture can make good attenuated live PRRSV vaccines that tend to confer the best protection 
to pigs subsequently challenged with the low passage parent isolate of the attenuated MLV 
vaccine (Mengeling, Lager et al. 2003). Nearly all of the animals in this study cleared the low 
passage parent challenge isolate while clearance of the other challenge isolates varied, with 
some variation even among the pigs within the same treatment group. Also supporting this 
evidence is a study conducted with a prototype Chinese PRRSV MLV vaccine that was 
shown to provide protection to vaccinated animals from a challenge with the virulent parent 
isolate of the vaccine (Tian, Zhou et al. 2008), (Tian, An et al. 2009). 
 The cross-protective immunity provided by PRRSV MLV vaccination has been 
evaluated in the respiratory model with mixed outcomes. Generally the results of the studies 
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indicate that there is some degree of cross-protection provided by one type of PRRSV to the 
other. In a single study both a NA PRRSV MLV vaccine and a EU PRRSV MLV vaccine 
were evaluated for efficacy against three different virulent EU PRRSV challenge isolates 
(van Woensel, Liefkens et al. 1998). It was determined that the EU PRRSV MLV vaccine 
provided the greatest level of protection with no viremia in the group challenged with the 
German PRRSV isolate and low levels of viremia in the Dutch and Spanish isolate 
challenged groups. The NA PRRSV MLV vaccine on the other hand only provided a 
significant reduction in viremia for the pigs challenged with the Spanish isolate. Two PRRSV 
MLV vaccines, one NA and the other EU, were again evaluated side by side for virological 
protection of the lung after a challenge with the LV isolate (Labarque, Van Gucht et al. 
2003). The number of pigs infected and the levels of viremia were reduced more for the 
homologous vaccine (EU), but the lung protection was not complete even for this group. The 
vaccination (Vaccine D) of piglets provided protection from viremia in a homologous EU 
PRRSV challenge, but not complete protection from viremia in a heterologous NA PRRSV 
challenge (Thanawongnuwech, Panyathong et al. 2006) (table 5). The vaccination induced 
the production of VN antibodies to the vaccine isolate, but not to either of the challenge 
isolates. The vaccination (Vaccine B) of animals has been shown to provide some protection 
from subsequent challenge with an EU type PRRSV isolate in the respiratory model 
(Nodelijk, de Jong et al. 2001) (table 5), (Roof, Gorcyca et al. 2000) (table 5). 
The use of EU type PRRSV MLV vaccines for evaluating the protection of pigs from 
respiratory disease has provided insight into the cell mediated response of the host in addition 
to revealing the variability in the protection provided from various challenge isolates. An in 
depth examination of the host immune response, focusing on cytokine expression and cell 
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stimulation as measured by RT-PCR and flow cytometry, after vaccination (Vaccine D) 
showed that no significant changes in cytokines or in CD4 and CD8 markers could be found 
(Sipos, Duvigneau et al. 2003) (table 5). Also, a similar CD8 single positive T cell curve 
could be seen for all vaccinated animals, showing an initial decrease followed by an increase 
between 22 and 40 days post vaccination with no increase in INF-γ. Although this data is 
interesting at an academic level it would be much more valuable if it were correlated with 
protection from a virulent challenge. In a respiratory study of vaccination (Vaccine D) the 
efficacy against challenge with either a closely related isolate or a less related isolate was 
tested (Labarque, Reeth et al. 2004) (table 5). No virus was detected in the vaccinated group 
after challenge with the closely related isolate, but after challenge with the less related 
isolate, virus was detected at levels that were significantly lower then the unvaccinated 
challenged animals. A vaccination (Vaccine D) study evaluating the protective efficacy 
provided to a closely clustered virus found that after challenge, all vaccinated animals still 
showed viremia during at least one sampling day, but the viremia seemed to be more 
sporadic in the vaccinated then in the un-vaccinated group (Prieto, Alvarez et al. 2008) (table 
5). Challenge virus was detected in the tissues of four of five animals in the vaccinated 
group, and in all of the un-vaccinated animals. Since the vaccine was not completely 
protective despite the high degree of genetic homology in the ORF5 gene between the MLV 
and challenge virus it was concluded that ORF5 homology might not be a good indicator of 
protection. In a later study two EU type PRRSV MLV vaccines were evaluated for their 
immunological properties and for protection from a subsequent virulent challenge (Diaz, 
Darwich et al. 2006). After vaccination, the animals had vaccine viremia, but did not develop 
VN antibodies, and once again the frequency of INF-γ secreting cells remained low. After 
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challenge with a virulent EU type PRRSV isolate one of the vaccines was shown to provide 
protection from viremia while the other vaccine did not. The vaccination (Vaccine D or 
Vaccine G; table 1) of pigs has also been shown in other studies to provide some protection 
from a subsequent EU PRRSV isolate challenge (Gozio and Woensel 2006) (table 5) and 
(Zuckermann, Garcia et al. 2007) (table 5) respectively. 
Therapeutic PRRSV MLV vaccination of animals, after exposure to virulent NA or 
EU PRRSV, is a topic of research that looks to mimic the conditions found in a PRRSV 
positive production setting. Pigs infected with a virulent PRRSV isolate (MN-30100) were 
vaccinated (Vaccine B) and subsequently challenged with a different highly virulent PRRSV 
isolate (Cano, Dee et al. 2007) (table 5 & table 7). The vaccination of these infected animals 
provided for a reduction in the duration of shedding but not in the overall viral load or the 
proportion of persistently infected animals. The results of the challenge indicated that 
vaccination provided for a significant reduction in clinical signs and enhanced weight gain, 
but no prevention of infection or shedding. In a well controlled setting, vaccine (Vaccine B) 
was administered after a wild-type VR2332 PRRSV infection and was able to reduced the 
duration of viral shedding and provided some protection from challenge with a highly 
virulent isolate (Cano, Dee et al. 2007) (table 5 & table 7). 
8.3 Respiratory field efficacy 
A field study was conducted using 10,000 six-week-old pigs vaccinated (Vaccine D) 
on a farm known to be PRRSV positive demonstrated that the vaccinated pigs outperformed 
the unvaccinated pigs by becoming ill less often and suffering less mortality (Mavromatis, 
Kritas et al. 1999) (table 5). The vaccinated pigs also showed better feed conversion resulting 
in a higher daily rate of gain. In another vaccination (Vaccine D) field study it was shown 
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that the vaccine provided a significant reduction in clinical signs after a challenge with a 
virulent EU PRRSV isolate of about 85% ORF5 sequence homology to the vaccine (Martelli, 
Gozio et al. 2009) (table 5). Efficacy in the field was evaluated by pig performance from 
birth through fattening and indicated that the vaccine (Vaccine D) provided limited efficacy 
with no differences in morbidity during the nursery or finisher phases, but significant 
reductions in morbidity were seen in the vaccinated animals during the grower phase (Kritas, 
Alexopoulos et al. 2007) (table 5). An across the board significant improvement in mortality 
for all ages of vaccinated pigs was observed and when compared to the unvaccinated pigs 
from unvaccinated sows, a significant improvement in the daily rate of gain was also seen for 
vaccinated animals. 
8.4 Laboratory reproductive efficacy 
 The reproductive efficacy has been evaluated extensively for both EU and NA 
isolates of PRRSV MLV vaccines in laboratory studies with varying levels of protection that 
is generally accepted a being better than the protection afforded by inactivated PRRSV 
vaccines. For example, when sows were vaccinated with either of two different NA PRRSV 
MLV vaccines they were better protected then sows vaccinated with an inactivated 
autogenous vaccine as indicated by increased piglet viability after a virulent PRRSV 
challenge (Osorio, Zuckermann et al. 1998). Vaccinated (Vaccine E or Vaccine G) pregnant 
sows produced more live born piglets and more weaned piglets then did the unvaccinated 
sows after a virulent challenge of all the animals (Scortti, Prieto et al. 2006) (table 6). The 
efficacy of an attenuated PRRSV isolate was found to be incomplete after it provided a 
reduction of piglet death loss in the vaccinated/challenged group, compared to the 
unvaccinated/challenged group, but also an increase in piglet death loss as compared to the 
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unvaccinated/unchallenged group (Mengeling, Lager et al. 1999). Vaccinated (Vaccine B) 
and unvaccinated pregnant sows were exposed to a mixture of 20 virulent PRRSV isolates 
showed that eight of the 20 isolates were found in the unvaccinated sows whereas two of the 
twenty isolates were recovered from the vaccinated sows. The two isolates found in the 
vaccinated sows were also among the eight isolates found in the unvaccinated animals. The 
study concluded that maternal immunization puts some selective pressure on a PRRSV 
challenge, and that this pressure is insufficient to prevent transplacental infection, and that 
the 20 challenge isolates used in the study must have differed in their ability to replicate in 
vivo and differed in their capability to cross the placental barrier in the sows (Lager, 
Mengeling et al. 2003) (table 6). The vaccination of three individual gilts each with one of 
three vaccines (Vaccine D, Vaccine E, or Vaccine G) resulted in the production of VN 
antibodies not only to the vaccine isolate but also to many other isolates with titers varying 
from those accepted as being protective to levels barely detectable (Mogedas, Martínez-Lobo 
et al. 2008). With such a small group size and the lack of a proper virulent challenge of the 
animals in this study it is impossible to make any conclusions on the potential protection 
provided from the VN antibodies elicited by the vaccines tested. A PRRSV MLV vaccine 
was evaluated off label to vaccinate boars and it was shown that the vaccine virus was in fact 
shed in semen, but for a shorter duration than virulent virus (Christopher-Hennings, Nelson 
et al. 1997). Vaccination of the boars reduced, but did not always eliminate the shedding of 
PRRSV after a subsequent virulent challenge and also seemed to negatively impact the 
quality of semen leading to the conclusion that the decision to use the MLV vaccine in boars 
should be made with caution and is not recommended.  
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Studies evaluating the reproductive cross protection provided by NA PRRSV MLV 
vaccination to heterologous challenge have shown that there are varying degrees of cross 
protective efficacy. The vaccination (Vaccine B) of animals has repeatedly provided 
protection from subsequent virulent NA type PRRSV challenge, but provides incomplete 
protection from challenge with EU type PRRSV isolates in the reproductive model (Glávits, 
Medveczky et al. 2002), (Medveczky, Kulcsár et al. 2002) (table 6), (Canals, Sánchez et al. 
2000) (table 6), (Roof, Gorcyca et al. 2000) (table 6). 
8.5 Reproductive field efficacy 
Field studies have been done which focus on the protection of both sows and their 
piglets from PRRS using MLV vaccines with mixed results. A placebo controlled field study 
of a EU PRRSV MLV vaccine in sows and gilts was performed to test the efficacy of the 
vaccine in pregnant animals (Pejsak and Markowska-Daniel 2006). The vaccinated animals 
had significant reductions in abortions and stillborn pigs as well as significant increases in 
live born pigs and weaned pigs per sow when compared to the unvaccinated animals, which 
contradicts the results of earlier negatively controlled laboratory studies in pregnant animals. 
Vaccination (Vaccine B) was used to stabilize a herd in China that suffered severe 
reproductive losses and sow deaths after PRRSV introduction leading to a reduction in 
stillborn and weak born piglets as well as reductions in death losses after weaning (Guo 
2008). Vaccination (Vaccine D) of an endemically PRRSV-infected herd resulted in a 
significantly increased farrowing rate and fewer returns to oestrus as well as more live born 
and weaned pigs in the vaccinated animals as compared to the unvaccinated animals 
(Alexopoulos, Kritas et al. 2005) (table 6). 
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8.6 Respiratory safety 
 The safety of PRRSV MLV vaccination has been evaluated in the respiratory model 
and the indications are that the vaccines pose only limited risk of reversion to virulence 
(Mengeling, Lager et al. 2003). Studies looking at not only safety but also efficacy in the in 
the respiratory model evaluating both vaccination (Vaccine B) or a multiple isolate PRRSV 
MLV vaccine prototype found that the vaccines performed similarly in regard to efficacy. 
However, the observation of enlarged lymph nodes in the unchallenged multiple isolate 
vaccinated group brought the safety of that vaccine into question. A study focused on the 
possibility for reversion to virulence of a vaccine isolate of PRRSV found that in some herds 
the PRRSV vaccine isolate may in fact persist long enough to mutate over time (Mengeling, 
Vorwald et al. 1999). 
8.7 Reproductive safety 
 PRRSV MLV vaccine safety has been a topic of research with some evidence of 
virulent vaccine-like isolates appearing in herds that were not actively vaccinating. Concern 
was raised in Denmark regarding swine herds that were suffering from the reproductive form 
of PRRSV caused by isolates that were very similar to vaccine (Vaccine B), and it was 
claimed that the new isolates were derived from that vaccine isolate (Botner, Strandbygaard 
et al. 1997). Again, in Denmark the investigation of vaccination (Vaccine B) raised questions 
about the safety of MLV vaccination. Similarities between some field isolates and vaccine 
isolates (Vaccine B) from which they were believed to have originated, supported the 
conclusion that several mutations in the ORF1 gene may have regenerated the genotype of 
the parent isolate in the vaccine isolate leading to the new more virulent field isolates 
(Nielsen, Oleksiewicz et al. 2001). An interesting observation was made in a swine herd that 
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utilized two different MLV vaccines at separate time points in an attempt to control PRRSV 
on a farm which was positive for PRRSV before beginning the vaccination program (Kiss, 
Sami et al. 2006). A number of post-vaccination new-outbreak isolates had genetic 
similarities to one of the vaccine isolates suggesting that the new isolates might have 
originated from the vaccine. 
 Forty-seven swine herds in Canada and the midwestern United States set out to 
determine if the use of a PRRSV MLV vaccine was safe in gestating sows (Dewey, Wilson et 
al. 1999). The results indicated that sows vaccinated at any point during pregnancy had a 
reduced number of live born and weaned pigs with an increase in the number of stillborn and 
mummified pigs when compared to the unvaccinated sows. The largest litter losses were 
observed in the sows vaccinated in the last four weeks of gestation, but the ultimate 
conclusion of the study remained that PRRSV MLV vaccines should only be administered to 
non-gestating animals. The reproductive parameters of sows after an initial vaccination with 
a NA PRRSV MLV showed that when the vaccine was administered during gestation it 
seemed to have contributed to a reduction in live born and weaned pigs also indicating that 
PRRSV MLV vaccines should only be administered to non-gestating animals (Dewey, 
Wilson et al. 2004). 
In contradiction to the previously mentioned studies some researchers have shown the 
safety of vaccination with PRRSV MLV vaccines. After being administered to naïve gilts on 
gestation day 60 a PRRSV MLV vaccine was found to be safe, with levels of piglet death 
loss in the vaccinated/unchallenged group similar to the unvaccinated/unchallenged group 
(Mengeling, Lager et al. 1999). Vaccination (Vaccine E or Vaccine G) has been shown to 
have no significant detrimental effects in pregnant gilts even though the vaccine isolates were 
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able to cross the placental barrier and infect the piglets (Scortti, Prieto et al. 2006). The 
reasons for the discrepancies between these studies and the ones mentioned previously could 
be attributed to any number of factors, but likely the problems can be found in the group 
sizes used. 
8.8 Novel applications and approaches to MLV vaccination 
New methods of producing MLV vaccines, the co-administration of probiotic bacteria 
with MLV vaccines, as well as the route of delivery for MLV vaccines have also been 
evaluated for the potential to provide enhanced efficacy. The growth of MLV vaccines 
(Vaccine H; table 1) in the ZMAC-1 cell line resulted in a significant reduction of viremia 
over the same vaccine grown the traditional way on MARC-145 cells after a virulent PRRSV 
challenge (Calzada-Nova, Husmann et al. 2008). The probiotic bacteria Lactobacillus casei, 
when administered orally in conjunction with PRRSV vaccination (Vaccine B) was found to 
be able to provide a significant increase in body weight gain when compared to the 
vaccinated only animals (Kritas and Morrison 2007). The probiotic, although very promising 
from the producers point of view for increased weight gain during PRRSV infection, was 
unable to provide any benefits over the MLV alone for reductions in the level or duration of 
viremia. No differences in the safety or the efficacy were observed for vaccination (Vaccine 
D), evaluated by the intradermal vaccination route as compared to the traditional 
intramuscular route of vaccine delivery (Cordioli, Alborali et al. 2004), (Drexler, Laar et al. 
2006), (Martelli, Cordioli et al. 2007). Protection from viremia was not complete with the 
vaccinated pigs being positive for viremia after challenge, but reductions were seen in both 
the level and the duration of viremia as compared to the unvaccinated challenged animals. 
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9. PRRSV Wild Type Exposure 
9.1 Background 
 Wild type PRRSV exposure is one of the more controversial strategies used by 
producers to protect their swine herds from PRRS. In its simplest form, this strategy consists 
of swine being intentionally exposed to a wild type PRRSV isolate, usually the predominate 
isolate found on the farm where the animals will be housed. The general theory behind this 
approach is based on the idea that the potential benefits of true homologous protection 
outweigh the potential losses associated with deliberately spreading the disease among a 
herd. This strategy takes on many forms, from simply commingling known positive pigs with 
naïve pigs, to more advanced methods of harvesting serum from an individual animal that 
was intentionally exposed to PRRSV, then injecting that animals virus containing serum into 
other swine. The strategy has evolved over time to become more complex and organized as it 
has gained following in the industry. It is currently one of the most popular strategies used in 
the United States (US) today and is likely second only to commercial vaccines for doses 
applied to swine. This strategy has intrinsic risks associated with its use including but not 
limited to the complete lack of government regulation, the lack of adequate quality controls, 
the probability of transmitting microorganisms other than PRRSV to naïve pigs, introduction 
of PRRSV clinical disease to a herd, the potential for PRRSV mutation or genetic drift, and 
the accidental exposure of neighboring farms to virulent PRRSV. Because of these risks and 
the risk of introducing a new PRRSV isolate into a herd, most production farms that use 
virulent exposure programs close their herds to replacement animals. Another drawback of 
live virus exposure is that the numbers of controlled laboratory studies specifically exploring 
the protection provided by this strategy are very limited, with much of the published research 
50 
available for this strategy being from field studies on farms that already have PRRSV 
problems. Additional issues that further confound the review of this strategy are the lack of 
any established standard dose and the lack of uniform methods for applying that dose. 
Perhaps the biggest two issues to consider for this strategy are the vast differences among the 
farm specific isolates used for immunizations along with the flawed hypothesis that each 
farm has only one isolate to protect from. This idea of one farm one isolate is disproved by 
the evidence for quasispecies, which would suggest that there are more than one isolate per 
pig let alone per farm. Because of these issues comparisons of studies to one another are only 
qualitative at best.  
9.2 Various virulence of wild type PRRSV 
Controlled laboratory studies have been done to examine the virulence of many 
different PRRSV isolates as well as the same isolate at different inoculation levels. Other 
studies have examined the transmission or clearance of PRRSV isolates from the host after a 
wild type exposure. Inoculation of naïve animals with one of nine different PRRSV isolates 
showed that differences existed in the abilities of the viral isolates to induce clinical signs, 
cause fever, and induce both macroscopic and microscopic lung lesions (Halbur, Paul et al. 
1996). A later study conducted in piglets using different wild-type (low passage), attenuated 
(high passage), or vaccine (USDA licensed) PRRS viruses at a low standardized dose 
replicated these results (Johnson, Roof et al. 2004). The study went further to show that 
viremia of varying lengths of time, and magnitudes could be statistically correlated to a 
corresponding difference in the humoral immune response of the piglets. To examine the idea 
that viremia levels impact disease, pigs were challenged with the same wild-type virus isolate 
at two different doses (Loving, Brockmeier et al. 2008). The goal was to determine if there 
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were differences in the hosts immune response to the same isolate at different inoculation 
doses. The outcome of this research showed that the inoculating dose of challenge virus did 
not significantly affect the level of viral RNA in the serum or the transcription of INF-γ, but 
it did affect the cell infiltration of the lung and the body temperature.  
Evaluations of wild type isolates from around the world describe vastly different 
levels of virulence. A highly virulent PRRSV isolate in China, which is characterized by two 
noncontiguous deletions in the Nsp2 gene was experimentally tested by exposing two-month-
old pigs to the virus (Zhou, Hao et al. 2008). The resulting clinical signs were similar to those 
observed in the field with the death of all pigs by day 21 post-infection. The prevalence of 
this type of PRRS is extensive in China with reports of the disease in 20 provinces, with 56 
field isolates being cataloged. At the opposite end of the spectrum a Chilean isolate of 
PRRSV was examined by exposing age-matched naïve pigs to one-month-old pigs 
previously infected with the wild-type PRRSV isolate for a specific and controlled amount of 
time (Ramirez, Moreno et al. 2008). It was observed that none of the animals in the study 
showed clinical signs with the exception of transient pyrexia. Viremia was detected in all 
infected as well as all contact exposed animals. In the sows exposed during late gestation a 
higher number of congenitally-infected and dead born piglets were seen, while sows exposed 
during mid gestation did not show the congenitally infected piglets leading to the conclusion 
that timing of virus exposure is an important consideration. The same results were again 
observed after a reproductive wild-type PRRSV exposure trial conducted in pregnant sows 
found that a challenge at day 90 of gestation was more severe than the same challenge at day 
45 of gestation (Mengeling, Lager et al. 1998). These differences in the challenge severity 
were similar to those found by Christianson et al. in 1993 with an increased likelihood of the 
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virus to cross the placenta and cause adverse affects at day 90 of gestation as compared to 
day 45 of gestation resulting in more fetal death after a gestation day 90 challenge. 
9.3 Intentional exposure to wild type PRRSV 
 The deliberate inoculation of naïve or sero-positive pigs with wild type isolates of 
PRRSV has resulted in several different outcomes. There is some evidence to support the 
idea that exposing swine to a virulent PRRSV isolate can provide up to a lifetime protection 
from a subsequent exposure to the same isolate (Lager, Mengeling et al. 1997). An 
evaluation of wild type PRRSV exposure as a means to stabilize sow herds concluded that 
the strategy “may have a place in some multiple site production systems” (Wagner 2005). 
Wagner explained the use of wild-type exposure in two scenarios; lingering clinical signs 
after a new isolate introduction to a farm or subpopulations of susceptible animals after a 
severe clinical break. In both of these examples abortions were observed after the sows were 
exposed to the wild-type PRRSV isolates, but to a lesser extent than those seen after the 
initial PRRSV break. A different examination focused on wild-type PRRSV inoculation of 
both naïve and previously exposed pigs and showed a significant reduction in lung lesions 
after exposure to a new virulent PRRSV challenge (Opriessnig, Baker et al. 2007) (table 7). 
The study also showed that exposure of pigs to wild type PRRSV isolates at either a low 
dosage or a high dosage resulted in a significantly reduced daily weight gain. The use of a 
wild type PRRSV inoculation for acclimation of PRRSV-naïve gilts to a farm specific 
PRRSV isolate was achieved by intramuscularly injecting serum from selected wild-type 
PRRSV positive animals (Fano, Olea et al. 2005). Infections among pigs on that farm were 
subsequently eliminated from within the fully segregated flow, but PRRSV was never 
eliminated from the partially segregated flow at the same farm. Again the acclimation of 
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PRRSV-naïve pigs on an endemic farm was accomplished, this time by commingling 
intentionally wild-type PRRSV inoculated and uninoculated age matched pigs at 6.5 weeks 
of age and at 10.5 weeks of age (Vashisht, Erlandson et al. 2008). The farm evaluating this 
method saw a slight improvement in the average number of pigs weaned only after it was 
depopulated, cleaned, and disinfected. The inoculation of sows with sera containing wild-
type PRRSV for the first time on a farm resulted in an acute reproductive failure with about 
600 abortions and even a few sow deaths, but once the herd was stabilized, pigs free of 
PRRSV were again weaned (Bruner 2007). A subsequent unexpected PRRSV break occurred 
on this same farm after a second round of sow inoculations took place with sera containing 
the same wild type PRRSV isolate. A study comparing wild type exposure to MLV 
vaccination demonstrated an increased level of VN antibodies and an earlier generation of 
INF-γ secreting cells in sows after wild type exposure as compared to the MLV vaccination, 
but a mean increase of 2.45 pigs per litter in the MLV group over the wild type exposure 
group was also observed (Lowe, Zuckermann et al. 2006). This increase in the pigs per litter 
was attributed mainly to the increased rate of conception failure in the wild type PRRSV 
exposed group. 
 The intentional inoculation of swine with wild type PRRSV is to say the least risky, 
and without the publication of more controlled laboratory studies examining the use of this 
strategy it becomes more difficult to differentiate between the attempted protection from 
PRRS and its cause. If this strategy is ever to be better understood, properly controlled 
laboratory studies will need to be conducted in which many of the complicating factors 
associated with field studies can be eliminated. Until these studies are done this strategy will 
remain an enigma as to its true potential for immunizing swine against PRRSV. 
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10. Conclusion 
 Killed PRRSV vaccines have the obvious advantage of safety, but the efficacy of 
these vaccines is poor with only limited protection demonstrated in rare cases. Since killed 
PRRSV vaccination is clearly safe, efforts in the development of improved killed vaccines 
would best focus on increasing efficacy. Adjuvants will likely to be the best option for this 
improvement, but other options that may provide adjuvant-like effects would be 
supplementation of the killed PRRSV vaccine with the addition of purified PRRSV antigens 
or combination vaccines including antigens that may help enhance the immune response to 
the PRRSV component within the vaccine.  
 Again, as with killed vaccines, subunit vaccines for PRRSV are very safe, but they 
currently lack adequate efficacy to be viable vaccine candidates. Subunit vaccines have been 
traditionally focused on the PRRSV structural proteins and more specifically the Gp5 
protein. The further investigation of the non-structural proteins for use as antigens is 
warranted. The focus of subunit PRRSV vaccine research should be the development of a 
more efficacious subunit vaccine with perhaps a more broadly applied approach than has 
been used in the past. Incorporation of both structural and non-structural antigens into new 
vaccine prototypes may provide an added benefit to subunit vaccination. 
 Both DNA and vector vaccines for PRRSV have the potential to be safe but seem to 
again provide incomplete protection. Only limited ranges of antigens have been evaluated 
using these methods so perhaps the use of different PRRSV antigens or combinations of 
antigens would provide increased efficacy. Another approach for the DNA and vector 
vaccinations could be the use of a prime-boost vaccination method. This method is often 
employed in cancer vaccination studies where a purified protein subunit vaccine is used to 
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prime the immune response of the individual, which is then followed by a boost with either a 
DNA vaccine or vector vaccine that is designed to express the same protein that was used in 
the prime. Perhaps broader ranges of either DNA vaccination plasmids or vector platforms 
need to be evaluated using the same PRRSV antigens that have already been evaluated in 
previous studies.  
 The safety and efficacy of PRRSV vaccines generated using infectious cDNA clones 
are likely comparable to a traditional MLV vaccine, but it is plausible that both could be 
improved over a traditional PRRSV MLV vaccine with proper design. The potential for the 
inclusion of specific DIVA characteristics in a PRRSV cDNA clone for use as a vaccine is 
intriguing, but needs to be tested for efficacy from a virulent challenge and if the DIVA site 
can be maintained after in vivo passage. If such a DIVA PRRSV vaccine were generated, 
shown to be safe and efficatious, and was subsequently licensed it is likely that it would 
quickly become the preferred method of PRRSV vaccination for many producers. 
 The commercially available traditional PRRSV MLV vaccination strategy has been 
shown to nearly always outperform other strategies when evaluated in a head to head 
challenge study. PRRSV MLV vaccination strategies may not work flawlessly against every 
PRRSV isolate every time they are applied, but after this review it is clear that this strategy is 
the best commercial option available to swine producers relative to a balance of safety and 
efficacy.  
At best, both the safety and efficacy of exposing pigs to wild type PRRSV is 
questionable and should only be used after careful consideration. This strategy not only 
produces clinical disease, and reductions in weight gain, but also abortions and death of sows 
in some more severe cases. Both the variability among the isolates tested and the variability 
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in the standards used for evaluation of this strategy are troublesome for comparing studies to 
one another. However, better comparisons could be made if whole genome sequence 
information were to be provided for the isolates used in a study and if a standard set of 
evaluation criteria was established for the presentation of data on wild-type-exposure. 
Furthermore, if more controlled laboratory style challenge studies were applied to the 
evaluation of the wild-type exposure strategy as opposed to the more traditional field 
challenge studies currently employed, more meaningful and more broadly applicable 
comparisons between studies of both this strategy and others could be made. The fact that 
even a wild type exposure does not provide broad immunity to PRRSV illustrates the scope 
of the challenge faced in the development of a broadly efficacious vaccine. 
While writing this review, it became very evident that there was a great need for 
standardization among all PRRSV researchers, not only for the study designs used to 
evaluate prototype PRRSV vaccines, but also for the primary parameters that should be 
included in all studies. In order to keep the development of PRRSV vaccines moving forward 
it is very important to remind all PRRSV vaccine researchers about a few very good 
suggestions, but one in particular could be considered the most important of all; always 
include a group vaccinated with a licensed commercial PRRSV vaccine in all study designs 
to serve as a direct comparison of the prototype vaccine being tested to something available 
in the marketplace today (Murtaugh, Dee et al. 2007). While examining the tremendous body 
of work published on PRRSV protection strategies it was absolutely astonishing to find that 
so much has already been tested and learned about PRRSV since its classification, yet so 
little is truly known about protection from PRRSV. Simply put, PRRSV has been, is now, 
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and will continue to be for at least the near future, one of the most significant and elusive 
pathogens researched in swine health. 
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Table 1. Commercial PRRSV vaccines. 
Vaccine Trade Name Manufacturer 
Vaccine 
Isolate 
Type 
Vaccine 
Category 
Vaccine 
Designation
PRRomiSe® Intervet Type II Killed Vaccine A 
Ingelvac® PRRS MLV Boehringer Ingelheim Type II Modified Live Vaccine B 
PROGRESSIS® Merial Type I Killed Vaccine C 
Porcilis® PRRS Intervet Type I Modified Live Vaccine D 
Amervac® PRRS Hipra Type I Modified Live Vaccine E 
Ingelvac® PRRS ATP Boehringer Ingelheim Type II Modified Live Vaccine F 
Pyrsvac-183® SYVA Laboratories Type I Modified Live Vaccine G 
PrimePac® PRRS Intervet Type II Modified Live Vaccine H 
 
 Table 2. PRRSV killed virus vaccination and subsequent respiratory challenge. 
                Vaccination                       Challenge                      Results          
Vaccine  a b c d e f g h i References 
Vaccine A N 10 IM 2 VR2332 0 n.d. ↔ ↑ (Nilubol, Platt et al. 2004) 
Prototype N 0.5 n/a 1 Ch-1a 20 n.d. ↓ n.d. (Cai, Guo et al. 2002) 
Vaccine C N 10 IM 2 n/a 35 n.d. ↓ n.d. (Reynaud, Charreyre et al. 2004) 
Vaccine C E 6 IM 2 n/a 35 n.d. ↓ n.d. (Reynaud, Charreyre et al. 2004) 
Vaccine C N 6 to 8 IM 2 PRRS120 35 n.d. n.d. n.d. (Piras, Bollard et al. 2005) 
Vaccine C N 20 IM 2 LV 28 n/a ↔ ↑ (Zuckermann, Garcia et al. 2007) 
n/a N 5 IM 1 I2 35 n.d. ↔ n.d. (Gozio and Woensel 2006) 
aSero-status (N = naïve, E = exposed), bAnimal age (weeks), cRoute of vaccination (IM = intramuscularly), dNumber of 
vaccinations, eChallenge virus, fChallenge timing (Study day), gLung lesions, hViremia, iVN antibody, n.d. = Not determined, ↔ = 
Not significant, ↑ = Significant increase, ↓ = Significant decrease, n/a = Not available. 
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 Table 3. PRRSV killed virus vaccination intramuscularly and subsequent reproductive challenge. 
       Vaccination                       Challenge                      Results          
Vaccine  a b c d e f g h i References 
Autogenous N gilts 3 IA-1-4-2 90 - ↑ ns ↑ ns ↓ ns (Osorio, Zuckermann et al. 1998) 
CyBlue® N boars 2 18794/93 - 35 n.d. n.d. ↔ (Nielsen, Nielsen et al. 1997) 
Vaccine C E sows 2 Field - - ↑ ↑ n.d. (Papatsiros, Koptopoulos et al. 2004) 
Suvaxyn®PRRS N gilts 2 2156 90 - ↔ ↑ ↔ (Scortti, Prieto et al. 2007) 
aSero-status (N = naïve, E = exposed), bAnimal age, cNumber of vaccinations, dChallenge virus, Field = Exposure to the PRRSV 
isolate(s) on the test farm, eChallenge timing (Gestation day(s)), fChallenge timing (Study day(s)), gLive born, hLive at wean, 
iViremia, n.d. = Not determined, ↔ = Not significant, ↑ = Significant increase, ↓ = Significant decrease, n/a = Not available, ns = 
in conjunction with an arrow specifies a change but no statistical difference was indicated. 
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 Table 4. PRRSV prototype vaccination and subsequent respiratory challenge. 
               Vaccination                              Challenge                       Results          
Vaccine  a b c d e f g h i References 
Subunit N 1 IM 2 MD-1 42 ↓ ns ↓ ns n.d. (Liao, Lin et al. 2004) 
Subunit N 2 IM 2 MD-1 42 ↓ ↓ ns n.d. (Liao, Yang et al. 2006) 
Subunit N 4 IM 2 TC-01 42 n/a ↓ n.d. (Liao, Weng et al. 2008) 
DNA N 3 IM 2 IAF-Klop 51 & 65 ↓ ns ↓ ns ↑ ns (Pirzadeh and Dea 1998) 
DNA N 3 ID 1 IAF-Klop 51 & 65 ↓ ns ↓ ns ↑ ns (Pirzadeh and Dea 1998) 
DNA N 3 IM 2 nd - n.d. n.d. ↔ (Jiang, Xiao et al. 2006) 
DNA N 4 IM 3 Ch-1a 63 ↓ ns ↓ ns n.d. (Hou, Chen et al. 2008) 
DNA N 4 IM 3 YA1 63 ↓ ns ↓ ↑ (Jiang, Fang et al. 2009) 
DNA N 3 IM 4 nd - n.d. n.d. ↑ ns (Kwang, Zuckermann et al. 1999) 
DNA N 3 IM 2 nd - n.d. n.d. ↑ (Li, Xiao et al. 2009) 
DNA N 3 GG 6 DK-111/92 126  n.d. ↔ ↑ ns (Barfoed, Blixenkrone-Moller et al. 2004)
DNA N 6 IM 3 5710 56 n.d. n.d. n.d. (Diaz, Domínguez et al. 2006) 
DNA N 4 IM 3 BS/114/L/2000 56 n.d. ↓ ns ↔ (Ferrari, Petrini et al. 2006) 
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 Table 4. (continued) 
 
                Vaccination                             Challenge                      Results           
Vaccine  a b c d e f g h i References 
Vector N 3 SC 1 16244B  60 n.d. ↓ ns ↑ns (Bastos, Dellagostin et al. 2004) 
Vector N 3 IN&IM 3 5710 0 n.d. ↓ ns ↑ns (Álvarez, Prieto et al. 2004) 
Vector N 4 IN&IM 1 Ch-1a 30 ↓ ns ↓ ns ↔ (Qiu, Tian et al. 2005) 
Vector N 4 IM 2 YA1 30 ↓ ns ↓ ns ↑ns (Jiang, Fang et al. 2007) 
Vector N 3 IM 2 SY0608 42 ↓ ↓ ↑ (Wang, Li et al. 2009) 
Vector N 3 IM 3 nd - n.d. n.d. ↑ (Rogan, Levere et al. 2000) 
Vector N 1 IN&IG 3 nd - n.d. n.d. ↑ (Alonso, Sola et al. 2002) 
Vector N 3 IM 2 Chang Chung 60 n.d. ↓ ↑ (Shen, Jin et al. 2007) 
Vector N 3-4 n/a 2 Olot 91 70 ↓ ns ↓ ns ↔ (Urniza, Ceriani et al. 2008) 
Clone N 8 IM 1 SDSU73 or LV 28 n.d. ↓ ns n.d. (Verheije, Kroese et al. 2003) 
Clone N 3 IM or IT 2 P129 42 ↓ ↓ n.d. (Welch, Jolie et al. 2004) 
Clone N 3 IM 1 SDSU73 21 ↓ ↓ ns n.d. (Wang, Liang et al. 2008) 
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 Table 4. (continued) 
 
aSero-status (N = naïve, E = exposed), bAnimal age(weeks), cRoute of vaccination (IN = intranasal, IM = intramuscularly, ID = 
intradermal, GG = gene gun, SC = subcutaneous, IG = intragastric, IT = intratracheal), dNumber of vaccinations, eChallenge virus, 
fChallenge timing (Study day(s)), gLung lesions, hViremia, iVN antibody, n.d. = Not determined, ↔ = Not significant, ↑ = 
Significant increase, ↓ = Significant decrease, n/a = Not available, ns = in conjunction with an arrow specifies a change but no 
statistical difference was indicated. 
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 Table 5. PRRSV modified live virus vaccination and subsequent respiratory challenge. 
         Vaccination                            Challenge                          Results        
Vaccine  a b c d e f g h i References 
Vaccine B N 4 IM 1 wt-7 or wt-11 28 ↓ ↓ns n.d. (Okuda, Kuroda et al. 2008) 
Vaccine E N 3 IM 2 02SB3 28 n.d. ↓ ns ↑ (Thanawongnuwech, Panyathong et al. 2006)
Vaccine E N 3 IM 2 01NP1 28 n.d. ↓ns ↑ (Thanawongnuwech, Panyathong et al. 2006)
Vaccine B N 4 IM 1 LV variable days n.d. ↓ n.d. (Nodelijk, de Jong et al. 2001) 
Vaccine B N 5 IM 1 CDI-NL-2.19 28 or 42 n/a ↓ n.d. (Roof, Gorcyca et al. 2000) 
Vaccine D N 6 IM 1 nd - n.d. n.d. n.d. (Sipos, Duvigneau et al. 2003) 
Vaccine D N 5 IM 1 LV or Italian 49 n.d. ↓ n.d. (Labarque, Reeth et al. 2004) 
Vaccine D N 4 IM 3 5710 0 n.d. ↓ ↑ns (Prieto, Alvarez et al. 2008) 
Vaccine D N 5 IM 1 I2 35 n.d. ↓ n.d. (Gozio and Woensel 2006) 
Vaccine G N 20 IM 2 LV 28 ↔ ↓ n.d. (Zuckermann, Garcia et al. 2007) 
Vaccine B E 6-8 IM 1-3 MN-184 97 n.d. ↓ n.d. (Cano, Dee et al. 2007) 
Vaccine B E 6-8 IM 1-3 MN-184 97 n.d. ↓ n.d. (Cano, Dee et al. 2007)  
Vaccine D E 6 IM 1 Field - n.d. n.d. n.d. (Mavromatis, Kritas et al. 1999) 
Vaccine D N 5 IM/ID 1 Field 45 n.d. ↓ n.d. (Martelli, Gozio et al. 2009) 
Vaccine D E 5 IM 1 Field - n.d. n.d. n.d. (Kritas, Alexopoulos et al. 2007) 64
 Table 5. (continued) 
aSero-status (N = naïve, E = exposed), bAnimal age (weeks), cRoute of vaccination (IM = intramuscularly, ID = intradermal), 
dNumber of vaccinations, eChallenge virus, Field = Exposure to the PRRSV isolate(s) on the test farm, fChallenge timing (Study 
day(s)), gLung lesions, hViremia, iVN antibody, n.d. = Not determined, ↑ = Significant increase, ↓ = Significant decrease, n/a = 
Not available, ns = in conjunction with an arrow specifies a change but no statistical difference was indicated. 
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 Table 6. PRRSV modified live virus vaccination and subsequent reproductive challenge. 
                   Vaccination                                      Challenge                    Results          
Vaccine  a b c d e f g h i References 
Vaccine E N gilts IM 1 2156 90 ↑ ↑ ↓ (Scortti, Prieto et al. 2006) 
Vaccine G N gilts IM 1 2156 90 ↑ ↑ ↓ (Scortti, Prieto et al. 2006) 
Vaccine B N gilts IM 2 pool of 20 viruses 90 ↑ ns n.d. ↓ ns (Lager, Mengeling et al. 2003) 
Vaccine B N gilts IM 1 n/a 90 ↑ ↑ n.d. (Medveczky, Kulcsár et al. 2002)
Vaccine B N pregnant sows IM 1 5710 90 ↑ ↑ ↓ (Canals, Sánchez et al. 2000) 
Vaccine B N gilts IM 1 CDI-NL-2.19 86-88 n.d. ↑ n.d. (Roof, Gorcyca et al. 2000) 
Vaccine D E gilts & sows IM 1 Field - ↑ ↑ n.d. (Alexopoulos, Kritas et al. 2005)
aSero-status (N = naïve, E = exposed), bAnimal age, cRoute of vaccination (IM = intramuscularly), dNumber of vaccinations, 
eChallenge virus, fChallenge timing (Gestation day(s)), Field = Exposure to the PRRSV isolate(s) on the test farm, gLive born, 
hLive at wean, iViremia, ↑ = Significant increase, ↓ = Significant decrease, n.d. = Not determined, , n/a = Not available, ns = in 
conjunction with an arrow specifies a change but no statistical difference was indicated.
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 Table 7. Initial exposure of naïve swine to wild type PRRSV followed by a subsequent challenge. 
       Exposure                                                          Results            
Virus a b Challenge c d e References 
Autogenous  8 IM VR3285, Day 70 ↓ ↓ ↑ (Opriessnig, Baker et al. 2007) 
SDSU-73 & Autogenous 3 & 8 IN & IM VR3285, Day 70 ↓ ↓ ↑ (Opriessnig, Baker et al. 2007) 
MN-30100 6 to 8 IN MN-184, Day 97 n/a ↓ n.d. (Cano, Dee et al. 2007) 
VR-2332 6 to 8 IN MN-184, Day 97 n/a ↓ n.d. (Cano, Dee et al. 2007) 
aAnimal age (weeks), bRoute of exposure (IN = intranasal, IM = intramuscularly), cLung lesions, dViremia, eVN antibody, ↑ = 
Significant increase, ↓ = Significant decrease, n/a = Not available, n.d. = Not determined. 
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Abstract 
Although much research has been performed on porcine reproductive and respiratory 
syndrome virus (PRRSV), little quantitative information is available on the relationships 
between virulence and in vivo virus replication, among isolates recovered at different times in 
the history of PRRS, or the relative levels of virulence associated with individual virus 
isolates. In this study the in vivo growth properties of virulent field isolates and attenuated 
PRRSV isolates were compared. The results show that virulent PRRSV isolates exhibit 
longer and more elevated levels of viremia, induce faster and more intense humoral immune 
responses, negatively affect body weight gain, induce higher death rates, and cause more 
severe clinical signs in a respiratory disease model. We found that the more virulent field 
isolates grew to significantly higher levels in pigs than did cell-culture adapted isolates. We 
concluded that the pathogenic consequences and immunological responses of pigs to PRRSV 
are directly related to viral load in acute infection as reflected in viral titers in blood. 
1. Introduction 
Porcine reproductive and respiratory syndrome virus (PRRSV) is an enveloped single 
stranded RNA virus classified in the family Arteriviridae (Cavanaugh, 1997). It causes a 
widespread disease of swine that was first described as ‘mystery swine disease’ in the USA 
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in 1987 (Hill, 1990). The disease manifests as respiratory illness in all age groups of swine 
leading to death in some younger pigs and severe reproductive problems in breeding age 
females.  
The dynamic nature of PRRSV allows for constant change in the disease and provides 
ample opportunity for the appearance of new strains (Andreyev et al., 1997; Murtaugh et al. 
1998; Meng, 2000). The fact that PRRSV changes so readily, coupled with its ability to cause 
devastating problems for swine producers makes it an important subject for research 
(Mengeling et al., 1998; Pejsak et al., 1997). Variation in levels of isolate virulence were 
demonstrated in lung lesions, and death in swine (Halbur et al., 1996), but efforts to link 
biological and immunological differences to specific genetic differences has been largely 
unsuccessful (Albina et al., 1998; Key et al., 2001; Yuan et al., 2001; Murtaugh et al., 2002; 
Grebennikova et al., 2004). Studies examining the safety and efficacy of PRRS vaccines 
include the work of Labarque et al. (2003), Mengeling et al. (2003a), and Nodelijk et al. 
(2001). These studies show that under experimental conditions modified live PRRS vaccines 
reduce the amount and duration of viremia as well as fever and lung lesions after virulent 
challenge. 
Opriessing et al. (2002) showed that isolates with high amino acid sequence 
homology in open reading frame 5 (ORF5) caused significantly different levels of pneumonia 
in pigs. Variation in swine responses to PRRSV also are affected by host variation 
(Mengeling et al. 2003b).Virulence has been examined in relation to replication rates and 
distribution of PRRSV in pigs (Haynes et al., 1997), to macrophage copper clearing 
capabilities (Thanawongnuwech et al., 1998), and the anemia levels of the host animal 
(Halbur et al., 2002). This study expands on the previous work by examining virulent field 
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isolates, their attenuated vaccine derivatives and highly virulent field isolates collected 
recently.  
The purpose of the present work was to examine the in vivo growth characteristics of 
and antibody responses to eight different PRRSV isolates with various known levels of 
virulence, so as to establish the relationship between in vivo replication of the virus, virulence 
and antibody response, and to test the hypothesis that in vivo replication of PRRSV is a key 
determinant of virulence and the level of humoral antibody response.  
2. Materials and Methods 
2.1 PRRS virus isolates 
 The PRRSV isolates used in this study are shown in Table 1. The isolates were 
chosen to span the history of PRRS and a range of virulence levels, and to represent relevant 
clinical disease manifestations. All of the virus isolates used in the study grew readily on 
CL2621 cells. Three of the primary field isolates also had attenuated forms of low or 
undetectable virulence that were derived by in vitro passage. The PRRSV isolate ATCC VR-
2332 was isolated in 1991 in Minnesota and was used at cell culture passage three, the 
attenuated form of this virus is commercially available under the trade-name Ingelvac® 
PRRS MLV (Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO). PRRSV SDSU 73 was 
recovered in Iowa from a severe case of reproductive disease in 1996 and was used at cell 
culture passage one. The attenuated form of SDSU 73, designated Abst-1, was obtained by 
52 passages. The PRRSV isolate 17198-6 was obtained from Oklahoma in 1997 from a herd 
experiencing severe reproductive disease and was used at passage level four. The PRRSV 
isolate JA 142, kindly provided by William Mengeling, National Animal Disease Center, 
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Ames, Iowa, was isolated in 1997 in Iowa from a severe “abortion-storm” case of 
reproductive failure and was used at cell culture passage five. The attenuated form of JA 142 
is commercially sold under the trade-name Ingelvac® PRRS ATP (Boehringer Ingelheim 
Vetmedica Inc., St. Joseph, MO). The PRRSV MN 184 isolate was obtained in 2001 from a 
swine farm experiencing severe reproductive disease and sow mortality in southern 
Minnesota and was provided by Kurt Rossow, University of Minnesota, St. Paul, and was 
used at a cell culture passage of one. Additionally, a pool of all isolates was produced and 
each pig in test group 9 was inoculated with two ml containing 103.71 total virus/ml. The 
virulent field isolates are quite distinct and represented a diverse group of PRRSV isolates, 
whereas the parental and vaccine PRRSV pairs were nearly genetically identical, as shown 
by the pairwise comparison in Table 2 and the dendrogram in Figure 1. The pairwise 
comparison and dendrogram were generated using the Lasergene software suite of sequence 
analysis tools (DNASTAR, Inc, (Madison, WI). 
2.2 Study Design 
One hundred healthy 2-3 week-old pigs were obtained from a PRRS-free commercial 
herd and were maintained at Veterinary Resources, Inc., Ames, Iowa, under the supervision 
of a veterinarian. Animals received food and water ad libitum. All of the animal care and 
laboratory personnel involved with the study were blinded to the treatments given to the 
various groups of animals. Pigs were tested negative by HerdCheck® PRRS ELISA 2XR 
(IDEXX Laboratories Inc. Westbrook, ME) and divided randomly by weight into 10 groups 
with 10 pigs per group. On day 0 each of the eight PRRSV isolates and the PRRSV pool 
were diluted to approximately 3.0 Log10 TCID50/ml in Eagle’s Minimum Essential Medium 
(EMEM) (JRH Bioscience, Lenexa, KS) containing 4% FBS (JRH Bioscience, Lenexa, KS) 
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and administered intranasally to pigs at a dose of 2 ml (1 ml per nostril). The untreated 
control group received 2 ml of media. The inocula were retitrated on 96-well plates 
containing three-day-old CL2621 cells for titer confirmation using the Reed-Muench method 
(Reed et al., 1938). The observed titers administered to pigs are shown in Table 1. 
2.3 Evaluation of Viremia 
Blood samples were collected by vacutainer on days 0, 1, 3, 7, 15, 21, 28, 35, 42, and 
49. Serum was separated from clotted whole blood by centrifugation at 3200xg for 20 
minutes. Serum samples were divided for analysis by virus isolation, Log10 TCID50/ml, 
quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), HerdCheck® PRRS 
ELISA 2XR, and PRRSV protein-specific ELISA. The serum samples in this study were 
processed immediately after collection and were chilled on ice within 3 hr. The samples were 
stored for a maximum of 24 hr at 4oC and at -70oC thereafter. Serum tested by RT-PCR was 
frozen at -70oC the day of collection and stored until the testing could be performed at which 
time only the number of samples that could be tested within 24 hours were thawed, extracted, 
and tested. 
Virus isolation was performed on three-day-old CL2621 cells (an MA-104 monkey 
kidney cell line) for samples collected on days 0, 1, 42, and 49. Viral titration was performed 
on days 3, 7, 14, 21, 28, and 35 using 100 μl of serum from each pig. Serum was diluted 
serially by ten-fold dilutions to a final dilution of 10-6 in tubes containing 900 μl of EMEM, 
2% FBS, 50 μg/ml gentamicin (Sigma Chemical Co. St. Louis, MO), and 2.5 μg/ml 
Fungizone (Invitrogen Corporation, Grand Island NY). Four replicates of each dilution were 
incubated on 96-well plates containing CL2621 cells, at 37oC and 4.5% CO2 for eight days. 
Each well then was examined for cytopathic effect (CPE) and the titers were determined 
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using the Reed-Muench calculation. 
To obtain viral RNA for quantitative RT-PCR the QIAamp Viral RNA Mini-Kit® 
(Qiagen Inc. Valencia, CA) was used as described in the kit instructions. A commercially 
available real-time, single-tube, RT-PCR assay for the detection of U.S. PRRSV was 
provided by Tetracore Inc. (Gaithersburg, MD) and used to detect PRRSV RNA. A minor 
groove binding (MGB) 5’ nuclease probe and primers were designed by alignment of 
GenBank isolates and based on conserved areas of the 3’ untranslated region (UTR). PRRSV 
RNA was reverse transcribed in a 25 μl single tube reaction consisting of Tetracore U.S. 
PRRSV Master Mix (18.9 μl Master mix, 2 μl Enzyme mix 1, 0.1 μl Enzyme mix 2) and 4 μl 
of extracted RNA. The reaction tubes were loaded into the Smart Cycler II® block (Cepheid, 
Sunnyvale, CA) and software settings of fluorescent detection were set for automatic 
calculation of the baseline with the background subtraction on. The thermal cycler program 
consisted of 52oC for 1800 s, 95oC for 900 s, and 45 cycles at 94oC for 30 s, 61oC for 60 s 
and 72oC for 60 s. A PCR reaction was considered positive if the cycle threshold (Ct) level 
was obtained at ≤ 45 cycles. For quantitation, known amounts of serially diluted in vitro 
transcript RNA product (1 x 10 -1 through 1 x 108 copies/μl) were used to generate a standard 
curve. Copy/ml concentrations of the unknown samples were determined by linear 
extrapolation of the Ct values plotted against the known concentration of the 3’UTR 
transcript product. 
2.4 Antibody Measurement 
ELISA S/P ratios were generated by performing the HerdCheck® PRRS ELISA 2XR 
according to the manufacturer’s instructions. PRRSV protein-specific ELISA was performed 
with recombinant isolate VR2332 nucleocapsid (N) and nonstructural protein 4 (nsp 4) which 
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were expressed in BL21 (DE3)-RP cells (Stratagene) from the plasmid pET 24b as fusion 
proteins containing an amino terminal myc-tag and a carboxyl terminal 6x histidine tag. 
Denatured proteins were dialyzed in 0.1 M Tris HCl, pH 8.0, 6 M guanidine-HCl, 2 mM 
EDTA and adjusted to a concentration of 3 mg/ml. DTT was added to 300 mM and the 
solution was filtered through a 0.45 µm membrane. Reduced protein was added into 
refolding buffer (100 mM Tris HCl, pH 8.0, 0.5 M L-arginine, 8 mM oxidized glutathione, 2 
mM EDTA, 10 μM pepstatin A, 10 μM leupeptin, and 1 mM PMSF), filtered (0.22 μm) and 
stirred overnight. The purified protein was concentrated by tangential flow filtration (Pellicon 
XL Ultracel PLC 5 kd, Millipore) and dialyzed against 20 mM Tris HCl, pH 8.0. Proteins 
were analyzed on an Agilent 2100 Bioanalyzer with the Protein LabChip. Purified protein 
solutions were stored at –80 °C. 
Protein-specific ELISAs were performed by coating microtiter plates with 100 ng 
recombinant protein in carbonate buffer, pH 9.6, or with buffer alone. Plates were blocked 
with 2.5% nonfat dry milk in phosphate-buffered saline containing 0.1% Tween 20 (PBST). 
One hundred µl of a 1:2000 dilution of serum was applied to duplicate wells for 2 h, after 
which plates were washed with PBST and antibody binding was detected by incubation with 
horseradish peroxidase-conjugated goat-anti swine IgG heavy + light chains (KPL, 
Gaithersburg MD) diluted 1:5000 for 1 hr, followed by washing and color development with 
100 µl of TMB substrate (KPL). Reactions were stopped with 1 M phosphoric acid and 
plates were read at 450 nm. 
2.5 Body Weights 
All pigs were weighed on day 0 (first day of study) and day 49 (end of study). Pigs 
were weighed on a portable electronic weigh-bar scale system Weigh-TronixTM model 
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615XL, (Weigh-Tronix Inc., Fairmont, MN). The scale was calibrated using certified test 
weights prior to and after each use. 
2.6 Clinical Scores 
On every day of the study each pig was scored by a veterinarian for respiratory signs, 
behavior, and coughing on a scale of one to four for each clinical sign. A normal animal was 
given a score of three, maximum clinical illness was a score nine and a dead animal received 
a score of 12. Samples from all animals that died in the study were submitted to the Iowa 
State University Veterinary Diagnostic Laboratory for pathological examination. 
2.7 Statistical Analysis 
 All data were imported into SAS version 8.02 for data management and analysis. 
Summary statistics including mean, standard deviation standard error, median and frequency 
distributions were generated for all out come variables as appropriate. Weight, RT-PCR, and 
Log10 TCID50/ml data were analyzed by one way ANOVA for overall differences among the 
treatment groups with pairwise testing for differences between treatment groups by Least 
Significant Difference t test. All tests for differences between groups were designed as two-
sided tests. Differences were considered statistically significant at p ≤ 0.05.  
Some changes were made to the data to facilitate correlation analyses. The Log10 
TCID50/ml values listed as <2.00 were set to 1.0. Negative RT-PCR values were set to 1.0 
and all RT-PCR values were normalized by transformation to log base 10 before analysis. 
Control group results were not included in the correlation analyses. Results for each pig were 
converted to an approximate area under the curve using trapezoidal rule (Hennen 2003). Area 
under the curve was computed for the entire study period, from the first observation to day 
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15, and from day 15 to the last observation, although only the entire study period is shown in 
the figures. 
3. Results 
3.1 Virus isolation and Log10 TCID50/ml quantification 
Before exposure on the day of infection no animals tested positive for PRRSV. At 1 
day after intranasal infection, only 13 animals in 5 groups tested positive for virus. However, 
at 3 days after infection all animals that were infected with field isolates, except for isolate 
17198-6, were virus positive with mean log10 TCID50/ml values ranging from 2.1 (SDSU-73) 
to 3.9 (MN 184). By contrast, animals inoculated with attenuated isolates were uniformly 
negative by cell culture (Figure 2). Peak levels of viremia, from 3.6 to 4.6 log10 TCID50/ml 
were attained on day 7 for four of five virulent isolates and titers remained near or above 2 
log10 TCID50/ml in all virulent virus groups for 21 days except for JA 142-infected pigs 
which had titers below that level. 
The levels of viremia in the pigs inoculated with attenuated PRRSV isolates were 
lower than in pigs inoculated with virulent field isolates. The Abst-1 isolate, with the 
exception of day 3 post inoculation, was never re-isolated. Ingelvac® PRRS MLV fluctuated 
between 0.5 and 1.0 log10 TCID50/ml from days 7 to 28, and Ingelvac® PRRS ATP varied 
between 0.4 and 1.2 log10 TCID50/ml from days 7 to 28. Attenuated isolate viruses were not 
recovered from serum after day 28, and virus was recovered from only two of the virulent 
field isolate groups, the pool-infected and MN 184-infected pigs through day 35 (Figure 2). 
Nearly all pigs were nonviremic by virus isolation at days 42 and 49. 
Overall, the more virulent isolates were observed to replicate faster and to higher 
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titers in pigs than were the attenuated isolates. Pigs infected with the MN 184 isolate, in 
particular, showed a very rapid increase in virus replication beginning before day 3 and 
reaching a peak of over 4.5 log10 TCID50/ml on day 7. After peaking, the MN 184 viremia 
steadily decreased but still maintained a significantly higher titer (t-test, p≤0.05) than all 
other isolates on days 28 and 35. A similar trend was observed in all of the remaining 
virulent groups, namely VR2332, JA 142, SDSU 73, and the pool (Figure 2). Pigs infected 
with 17198-6 followed the same general trend described for the MN 184 infected group but 
not as closely. Groups of pigs administered the attenuated isolates (Ingelvac® PRRS MLV, 
Ingelvac® PRRS ATP, and Abst-1) followed a different trend. They showed a moderate 
increase in viral titer beginning after day 3 that reached a peak between days 7 and 15 at a 
viral titer more than a log less than any of the virulent exposure groups and several orders of 
magnitude less than the MN 184-infected group. The titers observed in these attenuated 
exposure groups then declined to zero on or before day 35 (Figure 2). 
3.2 Virus quantification by real time RT-PCR 
Levels of viremia were also determined by real time RT-PCR since it was possible 
that growth on CL2621 cells was not the same for all strains and because real time RT-PCR 
might be a more sensitive measure than growth on cells for viremia. The virulent exposure 
groups showed a dramatic increase in average concentration on day 1 and all groups peaked 
above 8 logs/ml between days 7 and 15 (Figure 3). The virulent exposure group 
concentrations then gradually tapered off through the next several weeks, reaching 
concentrations below 4 logs/ml by day 49. The attenuated strain exposure groups showed a 
much less dramatic increase in concentration that also began around day 1 and the average 
group titer never reached or exceeded 7 logs/ml (Figure 3). The concentrations observed for 
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the attenuated exposure groups were maintained at fluctuating levels showing a wide range in 
values in the weeks following the exposure. The fluctuations were due to sporadically high 
values in a single pig. The three attenuated strain exposure groups all peaked on different 
days of the study. The Ingelvac® PRRS MLV group peaked at a concentration of 4.31 
logs/ml on day 28, the Ingelvac® PRRS ATP group peaked at 6.58 logs/ml on day 3, and the 
Abst-1 group peaked at 6.85 logs/ml on day 35 (Figure 3). The average concentration of the 
virulent isolate groups was observed to be significantly higher (P<0.05) than the average 
concentration of the attenuated strain groups on days 3 and 15, but on day 49 the average 
concentration of the virulent isolate groups was significantly lower (P<0.05) than that of the 
attenuated isolate groups. 
3.3 HerdCheck® PRRS ELISA 2XR 
The humoral immune response to PRRSV, as measured by HerdCheck® PRRS 
ELISA 2XR S/P ratios, showed that the virulent isolate exposure group averages rose above 
the 0.4 cutoff for a positive result on day 15. By contrast, the attenuated strain exposure 
group averages were negative and all three groups remained below 0.4 until after day 21. The 
Ingelvac® PRRS MLV and Ingelvac® PRRS ATP groups showed positive results on day 28, 
but the Abst-1 group did not show an average S/P ratio over 0.4 until day 42 (Figure 4). In 
comparing the humoral response of groups infected with virulent isolates or the pool to 
groups inoculated with attenuated strains, it was clear that the kinetics and magnitude of the 
antibody response was associated with the level of viremia, particularly between 14 and 35 
days after infection. This observation is further supported by the correlation between viremia 
levels and humoral antibody responses determined by paired comparisons of HerdCheck® 
PRRS ELISA 2XR S/P ratios to either virus titration or RT-PCR. Figure 5 and Figure 6 show 
104 
that the humoral antibody response is closely associated with viral load over the entire study 
period with a correlation coefficient r=0.858 for virus titration and r=0.794 for RT-PCR. 
These associations were highly significant (p<0.0001 in each case). Moreover, attenuated 
strains showed low antibody responses and viral loads, whereas virulent strains show high 
responses (Figures 5 and 6). 
3.4 PRRSV protein-specific ELISA 
To gain additional insight into the relationship between differences in PRRSV inocula 
and humoral immune responses, the antibody titers against N, the major structural protein, 
and nsp 4, an essential but minor nonstructural protease, were determined. The kinetics of the 
anti-N IgG response were nearly identical in all groups of pigs, with a peak titer on day 28 
followed by a sharp decline in the next 7-14 days, after which the levels were maintained or 
rose slightly between days 42 and 49 (Figure 7A). The magnitude of the response was similar 
to the HerdCheck® PRRS ELISA 2XR results, and consistent with the levels of viremia. The 
lowest peak titers at day 28 were observed in the groups inoculated with attenuated strains, 
and the highest titer was attained in pigs infected with the highly virulent MN 184 isolate. By 
day 49 the anti-N titer was equivalent in all groups except for MN 184 and the pool, 
suggesting that the humoral response to MN 184 may be qualitatively different. Also, only 5 
pigs survived to day 49 in each of these two groups, which is reflected in the increased 
standard error at day 49 in the MN 184 group. 
The IgG response to nsp 4 was substantially different than to N. No anti-nsp 4 
antibody was detected before day 21, the overall response was much weaker, and no 
significant response was detected in the groups receiving Ingelvac® PRRS MLV and Abst-1 
(Figure 7B). Moreover, the magnitude of the anti-nsp 4 response was not associated with 
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level of viremia. The responses to VR 2332, JA 142, MN 184, and the pool were all 
equivalent, with a peak at day 28, followed by a decline at day 35, then rising again at day 
42, whereas the magnitude, time course and duration of viremia varied among these four 
groups. When examining the summary measures analysis, presented as area under the curve, 
data for the nsp 4 ELISA compared to the Log10 TCID50/ml data, no significant correlation 
was observed between level of viremia and nsp 4 humoral antibody response (Figure 8).  
3.5 Body weight 
There was no significant difference in the mean weight of any of the groups on day 0 
of the experiment (P = 0.099). On day 49 pigs inoculated with the attenuated strain Abst-1 
had the highest mean weight, which was significantly higher then all other groups except for 
the control (Table 3). Also on day 49 the mean weights of all the virulent isolate exposure 
groups except for the 17198-6 group were significantly lower than the control group (Table 
3). The mean weights of the attenuated strain exposure groups Ingelvac® PRRS MLV and 
Ingelvac® PRRS ATP and the control group were statistically equivalent (Table 3). 
3.6 Clinical Scores 
Increases in average clinical scores were observed in only four of the virulent 
exposure groups: JA 142, SDSU 73, MN 184, and Pool. These higher scores were maintained 
throughout the study while the remaining groups, both virulent and attenuated exposures, had 
essentially normal clinical scores for the duration of the study. The only major cause of 
changes in the average clinical scores observed in this study occurred when one or more 
animals died in the associated treatment group (Table 4). The severity of clinical disease was 
highly associated with viral load (p<0.001 for virus titration). When examining the area 
under the curve as shown in Figure 9, the clinical scores were highest for the groups infected 
106 
with MN 184 and the Pool. Fifty percent of the pigs in each group died, and virus titration 
indicated that the level of infection was substantially higher than for all other groups (Figure 
9). The differences in viral load as determined by RT-PCR were less marked (data not 
shown) and the correlation of clinical signs with viral load by RT-PCR was less than with 
virus titration (r=0.556 versus r=0.803, respectively). The clinical scores in group 10 
(Control) increased after the death of two pigs from bacterial pneumonia. Both pigs were 
shown to be PRRSV negative by immunohistochemical staining of lung tissue, negative virus 
isolation and real-time PCR analyses, and the complete lack of seroconversion by 
HerdCheck® PRRS ELISA 2XR or protein-specific ELISA. The summary of findings from 
the Iowa State University Veterinary Diagnostic Laboratory indicated that various bacterial 
pathogens were present in animals that died unexpectedly during the study and these deaths 
were likely attributable to secondary bacterial infection (Table 5). 
4. Discussion 
The objective of this study was to examine various PRRSV isolates with known 
levels of virulence to determine if there was a relationship with in vivo replication that could 
be used to predict the virulence of PRRSV isolates without the necessity of performing 
controlled challenge experiments. In addition, it was of interest to determine the relationship 
between isolate virulence, levels of viremia, and the humoral antibody response. 
In order to test PRRSV isolates under the same conditions it was necessary to use 
dosages of licensed vaccines that were below the minimum immunizing dose established 
with the USDA and that were not representative of a commercial dose. Also, the intranasal 
route of administration of the MLV vaccines used in the study was not in accordance with the 
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USDA label and was only used to mimic a more natural exposure. The experimental doses 
used in the present study were not expected to and did not induce an immune response 
equivalent to the much higher commercial doses. Although not specifically addressed in this 
study, the effect of dose is likely much more significant for an attenuated or less virulent 
virus than it is for a virulent field virus that can quickly grow in and be recovered at over 4 
logs/ml in pig serum within 3-7 days of exposure. The higher recommended intramuscular 
commercial dose induces HerdCheck® PRRS ELISA 2XR S/P ratios above the 0.4 cutoff by 
14 days post vaccination which is one-half the amount of time observed for the doses used in 
this study (Roof et al., 2003). The nominal dose used in this study, 2 x 103 TCID50 per 
animal, caused 50% mortality in groups that received isolate MN 184, and anti-nucleocapsid 
responses in all groups. Higher doses were not tested since excessive mortality in groups 
challenged with highly virulent strains would have compromised the study objectives. In 
addition, previous studies had shown no difference in clinical signs and viremia in young 
pigs inoculated with PRRSV isolate VR2332 at doses of 102.2, 103.2 and 104.2 TCID50 per 
animal (unpublished data). 
Both the Log10 TCID50/ml and real time RT-PCR results showed that the viremia 
levels vary significantly among groups following PRRSV exposure, indicating that the 
growth rate of PRRSV in pigs is a phenotypic characteristic of the virus independent of 
possible variation in pig susceptibility to infection. In addition, attenuation of PRRSV by 
adaptation to growth on CL2621 cells reduced not only its ability to grow in pigs, but altered 
the kinetics of viral replication so that peak viremia occurred at later times. A similar 
observation was also made by Chang et al. (2002), who showed that even a limited period of 
cell culture passage of the moderately virulent PRRSV isolate VR 2332 reduced viral growth 
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in pigs and delayed significantly the time to peak viremia. However, a delayed time to peak 
viremia is not diagnostic for in vitro cell culture passage or for attenuation, since the highly 
virulent isolate 17198-6 also showed a delayed time to peak viremia. 
Overall, virulent isolates showed substantially higher viremia levels in serum than did 
attenuated strains at equivalent doses of inoculation. For example, the highest observed virus 
titer in any of the attenuated isolate exposure groups was 1.22 logs on day 15 in pigs given 
Ingelvac® PRRS ATP, whereas the lowest titer of any virulent group on day 15 was 2.40 
logs in the SDSU 73 group. The peak of viremia at days 3-7 and the levels of virus detected 
(all >3.5 logs/ml) was highly consistent among virulent PRRSV isolates, though MN 184 
was significantly greater in its magnitude and duration, with virus titers still present on days 
28 and 35. Our results support the concept that highly virulent PRRSV isolates replicate to a 
substantially higher titer in vivo than do attenuated or lowly virulent isolates, but they do not 
establish a direct quantitative relationship between level of virulence and level or rate of in 
vivo growth among wild-type PRRSV (Haynes et al. 1997). 
The real time RT-PCR results were statistically very similar to the Log10 TCID50/ml 
results, indicating that both methods measure relative levels of infectious virus among groups 
(data not shown). The Pearson correlation coefficient (r) between the RT-PCR and Log10 
TCID50/ml day 7 data was 0.89 and for the average real time RT-PCR and Log10 TCID50/ml 
results was 0.88. The concentration values determined by real time RT-PCR may have been 
several orders of magnitude higher than log10 TCID50/ml values for several reasons, 
including differences between the frequency of viral particles containing the target amplicon 
and particles that are fully infectious on CL2621 cells, and the presence of neutralizing 
antibodies that could lower infectivity (Dianzani et al., 2002). However, neutralizing 
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antibody is unlikely to account for the difference, since it was observed at all time points, 
including times before which an anti-PRRSV antibody response had been produced. 
In general, the ELISA observations support the concept that the magnitude of the 
humoral immune response is related to the level of viral replication during acute infection. 
The trend indicated in Figures 5 and 6 illustrates this relationship, a slower and less intense 
humoral immune response was triggered by the cell-culture attenuated virus isolates, whereas 
a faster and more intense humoral immune response was triggered by the virulent isolates. In 
addition these observations also demonstrate that at least two factors, isolate type and 
infectious dose, impact relative S/P ratio values in the HerdCheck® PRRS ELISA 2XR. 
Although the ELISA results shown in Figure 4 indicate a clear positive or negative average 
group response, it is important to note the variability among individual animals, some pigs 
within attenuated virus groups were positive before day 21, and some pigs in the virulent 
groups remained negative up to day 21. This information also shows that caution must be 
exercised to quantitatively evaluate and compare S/P ratios. Such comparisons are impacted 
by a variety of host, viral, and technical factors which limit their interpretation and could 
cause false conclusions.  
Analysis of specific antibody responses to N and nsp 4 show that immune responses 
to PRRSV vary in intensity independently of the inoculating isolate. Antibody responses to 
the N protein in animals that were inoculated with the highly virulent isolates MN 184 and 
JA 142 showed a trend similar to that of all the isolates but to a higher magnitude. Pigs 
inoculated with MN 184 and JA142 also had the highest viral titers, as shown in Figures 1 
and 2. Thus, it suggests that the level of humoral immune response may be related to the viral 
load in acute infection as measured by viral titer. Interestingly, the time course of response 
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was the same in all groups, even though the time to peak titer was delayed for highly virulent 
strain 17198-6 and the attenuated strains. The nsp 4 antibody response, by contrast, was low 
at all of the time points and for all of the isolates, both attenuated and virulent. However, the 
time course of anti-nsp 4 response was equivalent in all of the groups despite differences in 
the time to peak viral load among groups, as observed for the anti-N antibody response. All 
pigs regardless of treatment had low anti-nsp 4 responses relative to the anti-N response 
(Figure 7B). 
These observations indicate that some of the PRRSV proteins elicit a more robust 
response from the host immune system regardless of exposure isolate virulence. However, 
the observations also indicate that the magnitude of the immune response to the more 
immunogenic proteins is likely related to the virulence of the exposure isolate, or the ability 
of the isolate to replicate in vivo. It also is possible that differences in antibody response 
might be due simply to genetic differences among isolates that result in differences in 
antigenic reactivity such that antibodies directed against N and nsp 4 of other isolates do not 
react or react poorly to the recombinant proteins expressed from isolate VR2332 that were 
used to coat the ELISA plates. However, several lines of evidence suggest that the observed 
differences in antibody levels reflect immunologically relevant responses. Isolate MN 184 
shows the greatest genetic difference from VR2332, as determined by ORF 5 comparisons, 
yet has the highest anti-N antibody response. Kapur et al. (1996) showed previously that 
relative differences among PRRSV isolates in one open reading frame are also present in 
other open reading frames. Also, individual proteins contain conserved and nonconserved 
regions (e.g. Kapur et al., 1996) and extensive immunogenic reactivity may be directed 
toward the conserved epitopes (Ostrowski et al., 2002). Nevertheless, ELISA results based on 
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antibody reactions with purified PRRSV proteins may be affected by genetic and antigenic 
variation, and these effects must be considered. Refolding of recombinant proteins was 
performed since antigenic reactivity of N was higher in plates coated with refolded N, but no 
differences were observed between nonrefolded or refolded nsp 4 (unpublished data). 
It was noted that at approximately 4 to 5 weeks after inoculation a relatively large 
decrease in the antibody response to both the N and nsp 4 proteins occurred. A similar peak 
of 1 to 2 weeks followed by a decline of antibody reactivity was previously noted by Foss et 
al. (2002) for GP5, the major envelope glycoprotein. Taken together, these observations 
suggest that the response to individual viral proteins likely does not represent the full picture 
of the pig’s immune response to PRRSV since the humoral immune response as measured by 
the HerdCheck® PRRS ELISA 2XR does not show a similar transient peak of antibody 
reactivity. 
Reduced growth and mortality were the key correlates of virulence and viral in vivo 
growth rate. The lower mean weight observed in the virulent isolate exposure groups most 
likely reflected a difference in the ability of a PRRSV isolate to replicate in vivo and induce a 
more severe illness in the pig. These observations are consistent with previously reported 
data that PRRSV infection may cause anorexia with a 25 to 40 percent reduction in daily 
weight gain (Thacker, 2003). The clinical scores of most of the virulent isolate exposed 
animals showed rapid increases shortly after the inoculation, whereas there was virtually no 
change in the scores of the attenuated virus exposure animals. This increase in clinical signs 
was reflected in the observed death rates of 50%, 20%, and 10% in the virulent exposure 
groups receiving PRRS isolates MN 184, SDSU 73, and JA 142, respectively. In contrast, the 
attenuated exposure groups incurred no deaths. The relationship between rapid viral growth 
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and viral pathogenesis under the same conditions of viral exposure were most evident in 
comparing the groups exposed to MN 184 and Abst-1. The inoculation titers were virtually 
the same, 4.10 logs/ml and 4.18 logs/ml, respectively, and yet, as indicated in Figure 9, there 
were remarkable differences in the way the two isolates affected pigs. The Abst-1 isolate was 
nearly inert, it hardly replicated in vivo and caused no clinical signs. By contrast, the MN 184 
isolate replicated to extremely high titers in vivo and caused severe clinical signs, resulting in 
the death of 50% of exposed animals. Also notable, the group of pigs exposed to the pool of 
all virus isolates showed about the same virological, clinical, and immunological responses 
as pigs exposed to MN 184. This finding indicates that the most rapidly replicating virus in a 
mixed infection is likely to outcompete other isolates so that the net result is essentially the 
same as an infection with the single isolate having the highest growth potential. 
The notable in vivo differences between virulent and attenuated PRRSV isolates shed 
light on the relationship between the virulence of an isolate and its in vivo growth and 
replication. When administered at equivalent doses in pigs the more virulent isolates show 
Log10 TCID50/ml titers and RT-PCR concentrations that are exponentially higher than the 
attenuated isolates. The virulent isolates induce a more rapid and intense humoral immune 
response. The virulent isolates negatively affect weight gain and induce higher death rates 
and more severe clinical signs as compared to the attenuated isolates.  
Of note, this study emphasizes the variability in phenotypic characteristics of PRRSV 
in vivo. The interpretation of studies on PRRSV persistence, shedding, dissemination, 
transmission, immunity, and other interactions of PRRSV with pigs may be influenced by the 
isolates used in the study.  
In conclusion, the results of this study indicate that attenuated and virulent PRRSV 
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isolates induce remarkably different clinical signs, as well as immune responses that differ in 
intensity. We attribute these differences to the ability of the virus to replicate in vivo, a 
phenotypic characteristic that can be measured quantititatively in serum samples and may be 
developed for predicting the virulence of PRRSV isolates. 
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Table 1. Virulence and Inoculation Titer of Isolates. 
Group Isolate Year Isolated Virulence*** 
Titer Log10 
TCID50/ml
1 VR 2332 1991 Moderate 3.43 
2 Ingelvac® PRRS MLV* USDA license 1996 Attenuated VR2332 3.02 
3 JA 142 1997 High 3.13 
4 Ingelvac® PRRS ATP* USDA license 1999 Attenuated JA 142 4.14 
5 SDSU 73 1996 High 2.75 
6 Abst-1* Attenuated 1999 Attenuated SDSU 73 4.18 
7 MN 184 2001 High 4.10 
8 17198-6 1997 High 2.81 
9 Pool** N/A High 3.71 
10 Control N/A N/A N/A 
* Attenuated PRRSV isolates. 
** Mixture containing all of the eight isolates. 
*** Summary of lung lesions reported in Symposium on Emerging Diseases, Rome 2003. 
 Table 2. Pairwise comparisons of ORF5 nucleotide sequence of virulent and attenuated PRRSV isolates used in the study. 
 Percent Identity 
Percent Divergence VR 2332 
Ingelvac® 
PRRS MLV JA-142 
Ingelvac® 
PRRS ATP SDSU 73 Abst-1 MN 184 17198-6 
VR 2332  99.7 91.0 90.5 90.0 89.6 86.4 90.4 
Ingelvac ® PRRS 
MLV 0.3  90.7 90.2 89.7 89.2 86.4 90.0 
JA-142 9.7 10.1  99.2 92.7 92.2 87.2 92.2 
Ingelvac® PRRS 
ATP 10.3 10.7 0.8  91.9 91.4 86.4 91.4 
SDSU 73 10.9 11.3 7.8 8.8  99.5 87.2 91.7 
Abst-1 11.5 11.9 8.4 9.4 0.5  86.7 91.2 
MN 184 15.5 15.5 14.4 15.5 14.4 15.1  86.1 
17198-6 10.5 10.9 8.8 9.7 9.0 9.6 15.9  
Note: Percent similarity is shown in the upper right and percent divergence is shown in the lower left of the table.  
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Table 3. Average Body Weights. 
Isolate Day 0 Day 49 
VR 2332 6.381 33.5b 
Ingelvac® PRRS MLV 6.56 34.6* 
JA 142 6.42 32.7b 
Ingelvac® PRRS ATP 6.24 35.0* 
SDSU-73 6.59 32.9b 
Abst-1 6.69 39.4a 
MN 184 6.73 23.7c 
17198-6 6.36 34.5* 
Pool** 6.51 23.0c 
Control 6.48 38.4* 
1 Weights are in kg. There were no significant differences in mean wt at day 0. 
* Indicates statistically equivalent weights among these groups on day 49. 
** Pool was a mixture containing all eight isolates. 
a Significantly greater than all groups except the Control group (p≤0.05). 
b Significantly less than the Control group. 
c Significantly less than all other groups. 
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Table 4. Mortality of Pigs after Exposure 
Group  Strain  Mortality Day(s) of Death(s)  
 1  VR 2332  0/10  N/A 
 2  Ingelvac® PRRS MLV 0/10  N/A 
 3  JA 142  1/10 = 10% 17 
 4  Ingelvac® PRRS ATP 0/10  N/A 
 5  SDSU 73 2/10 = 20% 9, 23 
 6  Abst-1  0/10  N/A 
 7  MN 184  5/10 = 50% 14, 14, 17, 23, 41 
 8  17198-6  0/10  N/A 
 9  Pool**  5/10 = 50% 12, 16, 17, 21, 21 
 10  Controls  2/10* 41, 48    
 Attenuated PRRSV 0/30 = 0% 
 Virulent PRRSV 13/60 = 22%     
Note: All deaths in treatment groups were attributed to moderate or severe non-suppurative 
interstitial pneumonia due to PRRSV with secondary bacterial infection.  
* Deaths attributed to bacterial pneumonia with no PRRS involvement. 
** Pool was a mixture containing all eight isolates. 
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Table 5. Cause of Mortality after Exposure 
Pig # Group Cause of Death Day of Death 
993 JA 142 PRRS & Streptococcus suis 17 
948 Neg Control Arcanobacterium pyogenes & Pasteurella multocida 41 
983 Neg Control A. pyogenes & P. multocida 48 
922 SDSU 73 PRRS & bacterial pneumonia* 9 
918 SDSU 73 PRRS & Escherichia coli 23 
973 MN 184 PRRS & Actinobacillus suis 14 
992 MN 184 PRRS & A. suis 14 
980 MN 184 PRRS & E.coli 17 
971 MN 184 PRRS & E.coli 23 
958 MN 184 PRRS & E.coli 41 
976 Pool PRRS & A. suis 12 
970 Pool PRRS & S. suis 16 
972 Pool PRRS & S. suis 17 
995 Pool PRRS & S. suis 21 
969 Pool PRRS & A. pyogenes 21  
* The diagnostic report indicated “bacterial pneumonia” with no specific agent listed.  
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Figure 1. Genetic relatedness of the PRRS isolates. 
The bar indicates 1 nucleotide change per 100 residues. VR2332 is the parent 
isolate of Ingelvac PRRS MLV, JA 142 is the parent strain of Ingelvac PRRS ATP 
and SDSU 73 is the parent strain of Abst-1. 
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Figure 2. Mean virus titers in serum expressed as log10 TCID50/ml. 
The average titer of the MN 184 infected group at its peak on day 7 and on days 28 
and 35 was significantly higher (p ≤ 0.05) than all of the other isolates (asterisks). 
Viral titration was not performed on days 0, 1, 42, and 49 since less then 15% of 
the animals were virus-positive. 
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Figure 3. Mean PRRSV concentrations in serum by real time RT-PCR. 
The asterisk indicates the peak concentration of the virulent infected groups on day 
7. The double asterisk indicates the highest titer achieved by an attenuated isolate 
(Abst-1 on day 35). The treatment groups legend is the same as in Figure 2. 
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Figure 4. Mean HerdCheck® PRRS ELISA 2XR S/P ratios. 
All the virulent isolate groups showed HerdCheck® PRRS ELISA 2XR S/P ratios 
greater than 0.4 (positive result) by day 15 whereas all the attenuated isolate 
groups still show S/P ratios less then 0.4 (negative result) on day 15. The treatment 
groups legend is the same as in Figure 2. 
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Figure 5. Correlation analysis of the HerdCheck® PRRS ELISA 2XR and Log10 
TCID50/ml. 
Individual group values for the HerdCheck® PRRS ELISA 2XR S/P ratios and the 
Log10 TCID50/ml were determined from the area under the curve across all time 
points for each treatment group in the experiment as described in Materials and 
Methods. The X- and Y-axis values are relative units. Points are labeled according 
to treatment group. 
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Figure 6. Correlation analysis of the HerdCheck® PRRS ELISA 2XR and RT-PCR 
concentration. 
Individual group values for the HerdCheck® PRRS ELISA 2XR S/P ratios and the 
RT-PCR concentration were determined from the area under the curve across all 
time points for each treatment group in the experiment as described in Materials 
and Methods. The X- and Y-axis values are relative units. Points are labeled 
according to treatment group. 
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 Figure 7. Effect of PRRSV isolate or strain on antigen-specific IgG response. 
Sera were tested at a 1:2000 dilution on ELISA plates coated with 100 ng of 
recombinant VR 2332 nucleocapsid or nsp 4. Data are the mean values of 10 
animals, except where animals died. (A) Response to nucleocapsid. Error bars 
in the MN 184 data points are standard errors of the mean. (B) Response to 
nsp 4-specific IgG response. 
Johnson et al.
Figure 7
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Figure 8. Correlation analysis of the nsp 4 curve and Log10 TCID50/ml. 
Individual group values for the nsp 4 and the Log10 TCID50/ml were determined 
from the area under the curve across all time points for each treatment group in the 
experiment as described in Materials and Methods. The X- and Y-axis values are 
relative units and it should be noted that the Y-axis scale is different then the scale 
shown in Figure 5 and Figure 6. Points are labeled according to treatment group. 
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Figure 9. Correlation analysis of the clinical scores and Log10 TCID50/ml. 
Individual group values for the clinical scores and Log10 TCID50/ml were 
determined from the area under the curve across all time points for each treatment 
group in the experiment as described in Materials and Methods. The X- and Y-axis 
values are relative units. Points are labeled according to treatment group. 
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Abstract 
PRRSV causes an economically important swine disease and is an elusive target for 
vaccine development. Two prototype PRRSV DNA vaccines were investigated; with 
expression either driven by the muscle-specific synthetic SPc5-12 promoter, or by the 
ubiquitous CMV promoter constitutively. Ingelvac® PRRS MLV, a commercially available 
modified-live virus (MLV) vaccine, served as a positive vaccination control. Both DNA 
vaccines significantly reduced the level of lung lesions after virulent PRRSV challenge when 
each group was compared to the challenge control group. The MLV provided the best level 
of efficacy and significantly reduced the lung lesions as compared to all other challenged 
groups. The level of efficacy provided by the SELI method of DNA vaccination validates 
this vaccination concept and allows for more focused efforts on determining the most 
relevant immunogenic regions of the PRRSV. 
1. Introduction 
PRRSV is classified in the family Arteriviridae (Cavanagh 1997). This enveloped, 
positive sense single-stranded RNA virus causes widespread disease in swine first known as 
‘mystery swine disease’, which was described in the US in 1987 (Hill 1990); (Swenson, Hill 
et al. 1995). The respiratory form of the disease is found in all age groups of swine, and may 
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be severe enough to lead to death in some younger pigs (Johnson, Roof et al. 2004) or cause 
reproductive problems that in some cases can be very severe in breeding age females (Lowe, 
Zuckermann et al. 2006).  
Modified-live virus (MLV) vaccines are able to induce both cellular and humoral 
immune response in the vaccinated animal (Charerntantanakul, Platt et al. 2006). The use of 
PRRSV vaccines comprised of inactivated antigens has not been as successful at eliciting 
high levels of efficacy in vaccinated animals (Zuckermann, Garcia et al. 2007). When a 
killed vaccine is administered, the resulting host immune response is typically humoral, with 
little to no induction of a host cellular immune response (Meier, Galeota et al. 2003). A 
major benefit of DNA vaccination is that the plasmid constructs have the ability to stimulate 
both humoral and cellular immunity in the vaccinated animal (Kutzler and Weiner 2008) and 
(Dhama, Mahendran et al. 2008). Furthermore, the use of novel delivery methods, such as in 
vivo electroporation (EP) has allowed for high expression levels, as well as humoral and 
cellular immune responses to antigens at relatively low plasmid quantities (Luxembourg, 
Evans et al. 2007). This increase in efficacy favored the testing of DNA formulations 
containing a large number of plasmids, rather than single antigen-encoding sequences 
(Laddy, Yan et al. 2008). 
Finding a next generation vaccine for PRRSV is a difficult task. Work has been done 
with cDNA infectious clones of the virus as a new method of generating a more 
characterized MLV-vaccine (Wang, Liang et al. 2008); (de Lima, Kwon et al. 2008). DNA 
vaccination is also a subject of investigation; several studies have been done utilizing DNA 
vaccination with a focus on the structural genes of the virus (Pirzadeh and Dea 1998); (Jiang, 
Xiao et al. 2006); (Rompato, Ling et al. 2006); (Xue, Zhao et al. 2004). Some researchers 
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have even looked at DNA vaccination with the ORF1 region as a whole individually and in 
combination with viral structural genes (Barfoed, Blixenkrone-Moller et al. 2004). The study 
described here looks to comprehensively examine the PRRSV ORF1 gene in combination 
with the structural genes as a plausible antigen able to provide protection from challenge. 
Sequential Expression Library Immunization (SELI) is a new application of the 
established Expression Library Immunization (ELI) DNA vaccination concept (Johnston and 
Barry 1997). Rather than utilizing random fragments of DNA as is done with ELI, the basis 
of SELI is that the DNA fragments of interest are designed in a systematic and sequential 
manner. This strategy allows a single extensive open reading frame to be expressed as many 
small protein fragments within the host. The host, because of their smaller size, can more 
readily express the SELI constructs. In this study, the very large PRRSV replication complex 
ORF1a/b (approximately 12,000bp) was divided into cDNA clones that sequentially 
represented the entire open reading frame. Earlier investigations found that intramuscular 
administration of SELI DNA vaccines with expression via the CMV promoter combined with 
an aluminum phosphate-based adjuvant conferred partial efficacy from virulent PRRSV 
challenge (Vaughn and Stammer 2006). In the current study electroporation was investigated 
as a more efficient method for ensuring DNA vaccine plasmids entry into cells. 
As shown in Table 1 the cDNA clones comprising the ORF1a/1b regions were 
designated (A) through (M). Clone (A) utilized the authentic ORF1a ATG start codon. The 
remaining ORF1a/1b clones (B) through (M) have had an ATG start codon added to their 
respective 5’ coding regions. Additional cDNA clones representing the PRRSV structural 
proteins ORFs 2a, 2b, 3, 4, 5, 6, and 7 were also generated. By utilizing a combination of the 
SELI clones and structural clones, it was possible to vaccinate pigs with PRRSV DNA 
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vaccines that encompassed the PRRSV genome in its entirety (i.e. ORF 1a/1b (A) through 
(M) and ORFs 2 through 7).  
The results of this study indicate that the SELI DNA vaccination strategy via 
electroporation was beneficial in determining that this approach could confer partial 
protection from virulent heterologous PRRSV challenge, and that the expression pattern 
driven by the muscle-specific or ubiquitous promoters evaluated did not affect the degree of 
efficacy provided by the DNA vaccine prototypes. 
2. Materials and Methods 
2.1 PRRSV Plasmid DNA Vaccines 
RNA was purified from the PRRSV isolate 17198-6 or VR-2332 (see Table 1) by 
performing, as per kit instructions, the QIAmp Viral RNA Mini Kit, (QIAGEN Inc. Valencia, 
CA). 
Reverse transcription (RT) was performed on the extracted viral RNA using random 
hexamers (PerkinElmer, Waltharm, MA) as per manufacturer’s instructions. As shown in 
Table 2 specific primers were designed and utilized in the PCR step using reagents from 
PerkinElmer (Waltharm, MA) for amplification of the cDNA. The DNA resulting from this 
amplicication was then gel purified using Easy Clean DNA Spin Filters (Primm Labs, Inc. 
Boston, MA). Each of the purified DNA fragments was ligated into the pGem®-T Easy 
Vector System (Promega Corporation, Madison, WI) and then transformed into MAX 
Efficiency® DH5-αTM Competent Cells (Invitrogen Inc. Carlsbad, CA). 
All of the PRRSV SELI coding regions and structural genes were respectively sub-
cloned from the pGem®-T Easy Vector into the DNA expression vector pVC1650 
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(Abruzzese, Godin et al. 1999). The pVC1650 vector contains the CMV promoter to direct 
the expression of the PRRSV SELI constructs and structural genes in a broad range of 
eukaryotic cell types in a constitutive manner.  
Additionally, the PRRSV SELI coding regions and structural genes were respectively 
sub-cloned from the pVC1650 vector into the DNA expression vector pAV0245BNH 
(pAVBNH). The pAVBNH vector contains the VGX SPc5-12 promoter to direct the 
expression of the PRRSV SELI coding regions and structural genes in muscle cells (Li, 
Eastman et al. 1999).  
After sub-cloning each of the fragments into the respective vectors, endotxin-free 
plasmid preparations were generated by performing, as per kit instructions, the EndoFree 
Plasmid Giga Kit (QIAGEN Inc. Valencia, CA). 
2.2 PRRSV Modified Live Vaccine (Ingelvac® PRRS MLV) 
 Ingelvac® PRRS MLV, (Boehringer Ingelheim Vetmedica Inc. St. Joseph, MO) was 
the modified live vaccine used in this study as per product insert.  
2.3 Study Design 
The study consisted of pigs that were three-weeks-old at day 0 which were divided 
into five groups of ten animals each. One group was treated with the twenty-three SELI 
pAVBNH plasmids via electroporation on both day 0 and day 21 of the study. A second 
group was treated with the twenty-three SELI pVC1650 plasmids via electroporation on day 
0 and day 21 of the study. A third group received Ingelvac® PRRS MLV as per label 
indications on day 0 of the study. Finally two groups were not treated with a vaccine 
prototype, and served as challenge and strict controls. 
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Whole blood samples were collected for serum generation from each animal on study 
days 0, 21, 44, 45, 47, 51, 54, and 58. The serum was then stored at -70°C until analyzed. 
Pigs receiving the DNA plasmid vaccination regime were anesthetized just prior to 
electroporation of their respective vaccines with a combination product containing ketamine, 
xylazene and Telazol® (Fort Dodge Animal Health Inc. Fort Dodge, IA) at a dosage of 0.4 
mL to 0.6 mL per pig dependant upon animal weight. Plasmids were formulated in sterile 
water at a concentration of 0.33 mg/mL each for the pAVBNH vector and 0.66mg/mL each 
for the pVC1650 vector. Electroporation (EP) was performed using a CELLECTRA® 
constant current electroporation device and its intramuscular (IM) applicator and arrays 
(Person, Bodles-Brakhop et al. 2008). Briefly, the arrays consist of five electrodes (21 gauge, 
2 cm in length) arranged in a 1 cm circular display. The electrode array was inserted into the 
target tissue, and after verifying impedance; the plasmids were injected through a port 
situated in the middle of the circular array delineated by the electrodes. Four seconds after 
the plasmid administration, the EP pulses were applied: 3 pulses at 0.5 Amps, 52 
milliseconds/pulse, and 1 second between pulses. On the day of each DNA vaccination, the 
entire plasmid formulation was split into four and the EP injections were performed in four 
different sites on each of the anesthetized pigs to accommodate the injection volume. The 
area chosen for EP was the inside of the hind legs, targeting the semimembranosous muscle. 
Approximately 0.75 mL of pooled plasmid constructs was administered during each of the 
four EP injections.  
On study day 44 animals, all groups, excluding the strict control group, were 
challenged intranasally (IN) with 2.0 mL of the virulent PRRSV isolate JA142 at 4.44 
logs/mL, 1.0 mL per nostril. The titer of the virus was determined by tissue culture infectious 
139 
dose fifty on MA104 cells using the Reed-Muench calculation (Reed and Muench 1938). The 
study was terminated 14 days after this virulent PRRSV challenge (study day 58). 
2.4 Study Evaluation Criteria 
At the study termination the lungs of each animal were scored for total percent 
consolidation due to PRRSV infection. A general description of lung pathology observed and 
the percentage of pathology for each lung lobe was recorded at the time of necropsy. The 
total percent of lung pathology for each pig was determined by summation of percent lung 
pathology for each lung lobe (Straw, Backstrom et al. 1986). 
Virus isolations were performed on pre-challenge sera collected on day 44 and on all 
bleed days after the challenge. Briefly, 100µl of serum was used to inoculate three-day-old 
MA104 cells grown on 48-well tissue culture plates with EMEM, 2% FBS, 50 μg/ml 
gentamicin (Sigma Chemical Co. St. Louis, MO), and 2.5 μg/ml Fungizone (Invitrogen 
Corporation, Grand Island NY). The cells were incubated in a humidified chamber at 37oC 
with 4.5% CO2 for 8 days after inoculation with the study serum they were then observed for 
cytopathic effect (CPE). 
Real-time RT-PCR for detection of PRRSV was performed on pre-challenge sera 
collected on day 44 and on all bleed days after the challenge. Extractions were accomplished 
by utilizing the QIAGEN BioRobot Universal (QIAGEN Inc. Valencia, CA) for purification 
of viral RNA from serum using, as per kit instructions, the QIAmp Virus BioRobot MDx Kit, 
(QIAGEN Inc. Valencia, CA). The one step qRT-PCR was performed using a commercially 
available assay for the detection of U.S. PRRSV as per kit instructions (Tetracore Inc. 
Gaithersburg, MD). 
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HerdCheck® PRRS ELISA 2XR (IDEXX Laboratories Inc. Westbrook, ME) was 
performed to prescreen all animals prior to beginning the study and on all study bleed days, 
according to the manufacturer’s instructions.  
All animals were weighed on the day of first vaccination, the day of second 
vaccination, the day of challenge, and at study termination. Pigs were weighed on a portable 
electronic weigh-bar scale system Weigh-TronixTM model 615XL, (Weigh-Tronix Inc. 
Fairmont, MN). The scale was calibrated using certified test weights prior to and after each 
use. 
2.5 Statistical Analysis 
All data were imported into SAS version 9.1 for management and analysis. Summary 
statistics by treatment group including mean, median, standard deviation, standard error, 
confidence intervals, coefficients of variation, and frequency distributions were generated for 
all variables, where appropriate. 
Pairwise comparisons were made among and between treatment groups and the 
challenge control group. The strict control group was not included in the analysis. Two-sided 
results were reported and all comparisons were evaluated at α = 0.05. 
The primary parameter, percent total lung lesion score, were not normally distributed 
data and were analyzed using the nonparametric Kruskal-Wallis / Wilcoxon Two Sample 
Test. 
 Continuous variables serum RT-PCR, ELISA, and weights / average daily weight 
gains were analyzed by Analysis of Variance. The equality of variances among groups was 
evaluated by the likelihood ratio test. If group variances were significantly different, an 
adjustment for unequal variances was made. 
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Binomial data (present/absent) for sera virus isolations were analyzed by Fisher’s 
Exact Test. 
3. Results 
3.1 Lung Lesion Scores 
As illustrated in Figure 1 both the pAVBNH SELI vaccinated group and the 
pVC1650 SELI group had significantly reduced group average lung scores when compared 
to the challenge control group. The Ingelvac® PRRS MLV group had the largest reduction in 
group average lung scores when compared to the challenge controls and also had 
significantly reduced group average lung scores when compared to all other PRRSV-
challenged groups in the study. Because of the variability in lung scores within groups the 
individual animal lung scores are provided and can be found in Table 3. Although statistics 
were not performed on individual animal data, it is interesting to note that the pAVBNH 
SELI group had only one animal with a total lung score contributing to much of the group 
average score. 
3.2 Virus isolations 
As expected, only the MLV-vaccinated pigs were found to be viremic for PRRSV 
prior to challenge. All other pigs remained virus isolation negative until after PRRSV 
challenge. As shown in Figure 2 there was little difference in the postchallenge virus 
isolation between the PRRSV-challenged groups, with the Ingelvac® PRRS MLV group 
being the only group to show a significant reduction in viremic animals after challenge. 
Although not statistically significant, it is interesting to note that the Ingelvac® PRRS MLV 
group had the lowest percent virus isolation positive on every day post challenge, with no 
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MLV-vaccinated animals found to be viremic at necropsy. 
3.3 Virus quantification by real time RT-PCR 
Figure 3 illustrates that all of the challenged groups in this study showed the same 
general trend for the level of PRRSV RNA in the sera after challenge. All PRRSV-
challenged groups showed an increase in the level of PRRSV RNA in the sera until peaking 
at three or seven days post challenge, after which there is a decrease in the level of PRRSV 
RNA until necropsy at 14 days post challenge.  
One exception to this trend would be the Ingelvac® PRRS MLV group which not 
only had detectable levels of PRRSV RNA on the day of challenge, but then actually had a 
decrease in PRRSV RNA level in the sera one day post challenge. The levels of PRRSV 
RNA on Day 3 through Day 10 post challenge were comparable to the other PRRSV-
challenged groups. The Ingelvac® PRRS MLV group also had the lowest level of PRRSV 
RNA, less then 106 genomic equivalences (g.e.), of any challenged group at the end of the 
study. Even though the DNA vaccinated groups did show a reduction in the level of PRRSV 
RNA at the end of the study, both still had a group average of more than 107.5 g.e. of PRRSV 
RNA detected in sera. 
3.4 HerdCheck® PRRS ELISA 2XR 
As shown in Figure 4 the Ingelvac® PRRS MLV group showed a typical humoral 
immune response after vaccination, while the SELI groups showed no seroconversion until 
after virulent challenge. The lack of detectable seroconversion using the IDEXX PRRS 
ELISA could possibly be explained, at least in part, by low levels of expression of the DNA 
vaccines by the pigs or an insufficient dose to elicit a response. The two SELI DNA vaccine 
groups had group average (S/P) ratios above the 0.4 positive cut off level on day 7 post 
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challenge, which is sooner then the challenge control group. A possible explanation for this 
earlier seroconversion would be the expression of PRRSV ORF 7 at a low level in the DNA 
vaccinated animals resulting in an anamnestic response. 
3.5 Body weight 
No group had a significant increase in average daily weight gain as compared to the 
challenge control group.  
4. Discussion 
The objective of this study was to evaluate the efficacy of prototype PRRSV DNA 
vaccines utilizing either the SPc5-12 or CMV promoter administered via electroporation 
against that of a commercially available PRRSV MLV vaccine using the host animal in a 
controlled trial. 
It is apparent from the lung lesion data that either of the promoters (SPc5-12 or 
CMV) in PRRS SELI DNA plasmids were able to provide a significant level of lung 
protection, as both of these groups showed a significant reduction in lung lesions when 
compared to the challenge control group. It is interesting to note that, with the exception of 
one animal, the individual lung consolidation scores of the pAVBNH SELI group were 
similar to those seen in the Ingelvac® PRRS MLV group following challenge. It has been 
observed before that expression of DNA vaccines in muscle cells can provide for antigen 
presentation and subsequent cell mediated protection from influenza challenge in mice 
(Ulmer, Deck et al. 1997). When the Ingelvac® PRRS MLV-vaccinated group was 
evaluated, it was clear that the MLV provided the highest level of efficacy and was able to 
significantly reduce the group average lung lesions when compared to all the other test 
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groups in the study. As this study was only designed to test the effect of the mode of delivery 
and promoter usage on the SELI concept, future studies will be needed to focus on the 
elucidation of the specific clones that are important for providing protection as well as the 
doses of these clones required to provide the protection. 
Although a reduction of lung lesions is the main measure of efficacy for a respiratory 
PRRS vaccine and has been correlated with cellular immunity (Charerntantanakul, Platt et al. 
2006), it was not the only parameter measured in this study. The presence of replicating virus 
in the serum post challenge is also a very good indicator of vaccine efficacy. According to 
the virus isolation results in this study, the two SELI vaccine groups did not afford a 
significant reduction in the presence of viable virus in serum following PRRSV challenge 
when compared to the challenge controls. Both of the SELI groups showed that at least 30% 
of the animals were virus isolation positive on the five sampling days post challenge. Also, 
with the exception of the Ingelvac® PRRS MLV-vaccinated group, it was observed that 
100% of the animals in PRRSV-challenged groups were virus isolation positive at seven days 
post challenge. The Ingelvac® PRRS MLV-vaccinated group showed both a shorter duration 
of virus isolation positive animals (three out of the five sampling days) and fewer animals 
virus isolation positive between challenge and necropsy, with a peak of (70%) viremic 
animals three days post challenge. 
Quantification of PRRSV RNA in each animal’s serum was achieved using real time 
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). None of the test 
groups in the study were found to have a significantly reduced post challenge level of 
PRRSV RNA in the sera when compared to the unvaccinated challenged group. It has been 
observed previously that the cell culture-based virus isolation and the qRT-PCR assays 
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indicate different levels of viremia (Johnson, Roof et al. 2004). It is important to remember 
that both assays provide valuable information as to the state of viremia post challenge. 
However, it is important to be cognizant of the differences between these two assays as the 
virus isolation assay detects only viable PRRSV, whereas the qRT-PCR detects both viable 
and non-viable PRRSV. The disparity in the two assays is evident in that the qRT-PCR 
indicated that every PRRSV-challenged pig on every post challenge sampling day tested had 
PRRSV RNA detected in their serum, whereas virus isolation results revealed many animals 
were negative for viable virus at the end of the study (data not shown). 
The level of seroconversion to PRRSV was determined through the use of the IDEXX 
PRRS ELISA. It is important to note that this ELISA is designed to detect seroconversion to 
the nucleocapsid protein encoded by the viral ORF 7 gene. For this reason a measurable pre-
challenge humoral immune response would not be expected for the groups vaccinated with 
the SELI prototypes, unless the ORF 7 gene expressed at levels equivalent to those seen in 
the animal during viral replication. It was interesting to note that by seven days post 
challenge the SELI vaccinated groups showed a group average S/P ratio above 0.4 (cut-off 
for a positive result) while the challenge control group average S/P ratio remained below 0.4. 
This shortened duration of time between virulent PRRSV exposure and seroconversion to a 
group average S/P ratio above 0.4 does suggest an anamnestic response to ORF 7 was 
induced by ORF 7 expression following the SELI DNA vaccinations. The level of ORF7 
expression was very likely below the levels seen during a natural PRRSV infection or 
vaccination with a PRRS MLV vaccine. Since this study was designed to test the mode of 
delivery and promoter usage for the SELI concept, further testing is needed to determine the 
PRRSV-specific genes or regions of genes important in conferring protection. The use of 
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only relevant plasmids will reduce the overall number of plasmids in the preparations and 
allow for the inclusion levels of the remaining, most relevant, plasmids to be increased. If a 
higher inclusion level of only the relevant plasmids were used and if the expression of these 
plasmids were close to or equivalent to those seen during viral replication in the host, better 
protection could be seen. As for the Ingelvac® PRRS MLV group, a typical seroconversion 
curve was observed with an S/P ratio of about 2.0 reached by Day 21 and then maintained 
throughout the duration of the study. 
In conclusion, PRRSV SELI DNA vaccines administered via electroporation and 
utilizing either the CMV or SPc5-12 promoter can reduce the level of lung lesions following 
virulent challenge, but it was apparent that the DNA vaccine prototypes evaluated in this 
study did not provide the same level of protection as was provided by Ingelvac® PRRS 
MLV. At this time, the costs for plasmid production, the practicality of the route of delivery, 
and the actual amount of DNA vaccine material needed for dosage of large animals in a 
production setting are major drawbacks to the use of DNA vaccines. The goal is lofty for a 
PRRS DNA vaccine but if the number of SELI plasmids can be reduced and the 
concentration of the remaining relevant plasmids can be increased then sufficient protection 
may be achievable. Therefore, further vaccination/challenge studies with selected SELI 
fragments would serve as an effective tool in the delineation of the relevant immunogenic 
regions of the PRRS virus.  
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Table 1. PRRSV SELI Fragments. 
Plasmid 
Designated 
clone Region of clone 
Nucleotide span of clone (using 
Genbank U87392 as reference) 
1 A ORF 1a 190-1128 
2 B ORF 1a 1126-2082 
3 AB ORF 1a 190-2082 
4 C ORF 1a 2082-3057 
5 D ORF 1a 3037-3990 
6 E ORF 1a 3985-4923 
7 F ORF 1a 4924-5880 
8 G ORF 1a 5863-6819 
9 FGa ORF 1a 4924-6819 
10 H ORF 1a 6808-7659 
11 I ORF 1b 7735-8651 
12 J ORF 1b 8634-9605 
13 K ORF 1b 9588-10553 
14 L ORF 1b 10536-11318 
15 M ORF 1b 11298-12071 
16 ORF2a ORF2a NA 
17 ORF2b ORF2b NA 
18 ORF3 ORF3 NA 
19 ORF4 ORF4 NA 
20 ORF5 ORF5 NA 
21 ORF6 ORF6 NA 
22 ORF5-6a ORF5 and ORF6 NA 
23 ORF7 ORF7 NA 
Note: Gray highlighted clones were generated from genetic material purified from PRRSV 
isolate VR-2332. All remaining clones were generated from genetic material purified from 
PRRSV isolate 17198-6. 
a Indicates the two clones that were not generated in the pVC1650 plasmid. 
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Table 2. PRRSV Cloning Primer Pairs. 
Designated 
clone 
Region of 
clone Forward primer Reverse primer 
A ORF 1a acatgtctgggatacttgat attaacttgcagcctccg 
B ORF 1a ccatgggtctccgagcagta ggtgacccggttggtttt 
AB ORF 1a acatgtctgggatacttgat ggtgacccggttggtttt 
C ORF 1a ccatgaacaaaaccaaccg caaatccaggggctcgtc 
D ORF 1a acatggacgagcccctggat gcacaatagagtaaaagc 
E ORF 1a ccatgtgcctctttttatgt ccctgaaggcttggaaat 
F ORF 1a caatgggcccacatctcatg agtccatccatccgtgca 
G ORF 1a acatgacggatggatggact attgagtctcatagcgag 
FG ORF 1a caatgggcccacatctcatg attgagtctcatagcgag 
H ORF 1a ctatgactggtgccctcgc gtcaattattcttttcagtt 
I ORF 1b gcatggttgttactgaaac ccagttttctcgcacagc 
J ORF 1b ccatggtgcgagaaaactgg cctgagtttttcccacat 
K ORF 1b ccatgtgggaaaaactcagg cctgacaggtttttccac 
L ORF 1b ccatggaaaaacctgtcagg ggacgcagcaacttctcg 
M ORF 1b ccatgcgagaagttgctgcg tcaattcaggcctaaagt 
ORF2a ORF2a aagcttgaaccgccatggaatg ggatccacaccgtgtaattcacta  
ORF2b ORF2b gccaccatgggggctatgcaaagccttttc ttaactccccaggtggggat 
ORF3 ORF3 aagcttccgccatggttaatagc  ggatccacatacacgggtgtccct 
ORF4 ORF4 ccaccatggctgcgtcccttctt ggatccatacttaaacattcaaattgc 
ORF5 ORF5 ccgccatggtggggagatgcttg gggatccatgacaaaagtcgtctaggg 
ORF6 ORF6 aagcttcagcgccgccatggggtcg gggatccttatttggcatatttgac 
ORF5-6 ORF5 & ORF6 ccgccatggtggggagatgcttg gggatccttatttggcatatttgac 
ORF7 ORF7 cgcggccgcaaatatgccaaataacaacgg tgcggccgcctcaagaatgccagccc 
Note: Gray highlighted portion of the primers indicates the ATG start codon for each of the 
fifteen SELI clones. 
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Table 3. Lung Involvement of Individual Animals by Treatment Group. 
Animal pAVBNH SELI 
pVC1650 
SELI 
Ingelvac® 
PRRSMLV 
Challenge 
Controls 
Negative 
Controls 
1 3.35 3.00 0.10 13.00a 1.10 
2 0.60 8.85 7.00 4.85 0.00 
3 0.85 33.50a 0.00 15.75a 0.00 
4 3.10 6.70 0.60 9.50 0.00 
5 3.50 10.00a 1.50 15.00a 1.25 
6 2.45 0.10 0.10 2.00 0.00 
7 1.00 11.25a 2.75 19.00a 0.00 
8 2.50 2.35 0.00 21.00a 0.00 
9 30.00a 0.55 0.10 14.50a 0.00 
10 8.25 1.10 0.00 9.00 0.00 
a Indicates animals with lung involvement greater than or equal to ten percent, an arbitrary 
value chosen to illustrate differences between the groups. 
Notice the pAVBNH DNA vaccinated group has only one animal or 10% of the animals in 
the group with involvement greater then ten percent while the challenge control group has 
60% of the animals with involvement greater then ten percent. 
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Figure 1. Percent Lung Involvement by Treatment Group. 
a Both the pAVBNH SELI group and the pVC1650 SELI group have significantly lower lung 
involvement then the challenge control group P = 0.0126 and 0.0494 respectively. 
b The Ingelvac® PRRS MLV group has significantly lower lung involvement then the 
pAVBNH SELI group, the pVC1650 SELI group, and the challenge control group. 
c The challenge control group has significantly higher lung involvement then all of the test 
groups. 
d The strict control group was not included in the statistical analysis.  
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Figure 2. Percent Virus Isolation Positive Animals by Treatment Group and Day-Post-
Challenge (dpc). 
a The only group to show a significant reduction in the percentage of viremic animals after 
challenge when compared to the challenge control group was the Ingelvac® PRRS MLV 
group at 7 and 10 days post challenge (dpc) P = 0.0108 and 0.0198 respectively. 
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Figure 3. Real Time PRRSV RT-PCR by Treatment Group and Day-Post-Challenge 
(dpc). 
a The only group to have animals positive for PRRSV genomic material on the day of 
challenge (study day 44 or 0dpc) was the Ingelvac® PRRS MLV group. 
b Although not statically significant is was also observed that there was a greater than one log 
reduction in the level of PRRSV genomic material in the Ingelvac® PRRS MLV group as 
compared to all other challenged groups at the time of necropsy (study day 58 or 14dpc). 
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Figure 4. IDEXX PRRS ELISA Group Average S/P Ratio by Study Day. 
a The Ingelvac® PRRS MLV group shows a typical IDEXX ELISA response to vaccination 
with seroconversion of all animals by study day 21.  
b Although not statically significant it was also observed that both of the DNA vaccinated 
groups showed a group average S/P ratio above 0.4 (positive result) by study day 51 (7dpc) 
while the group average S/P ratio of the challenge control group remained below 0.4 
(negative result). 
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CHAPTER 5. GENERAL CONCLUSIONS 
 
In order to keep the development of PRRSV vaccines moving forward it is very 
important to remind all PRRSV vaccine researchers about a few very good suggestions, but 
one in particular could be considered the most important of all; always include a group 
vaccinated with a licensed commercial PRRSV vaccine in all study designs to serve as a 
direct comparison of the prototype vaccine being tested to something available in the 
marketplace today.  
The notable in vivo differences between virulent and attenuated PRRSV isolates shed 
light on the relationship between the virulence of an isolate and its in vivo growth and 
replication. When administered at equivalent doses in pigs the more virulent isolates show 
Log10 TCID50/ml titers and RT-PCR concentrations that are exponentially higher than the 
attenuated isolates. The virulent isolates induce a more rapid and intense humoral immune 
response. The virulent isolates negatively affect weight gain and induce higher death rates 
and more severe clinical signs as compared to the attenuated isolates. Attenuated and virulent 
PRRSV isolates induce remarkably different clinical signs, as well as immune responses that 
differ in intensity. We attribute these differences to the ability of the virus to replicate in vivo, 
a phenotypic characteristic that can be measured quantititatively in serum samples and may 
be developed for predicting the virulence of PRRSV isolates. 
PRRSV SELI DNA vaccines administered via electroporation and utilizing either the 
CMV or SPc5-12 promoter can reduce the level of lung lesions following virulent challenge, 
but it was apparent that the DNA vaccine prototypes evaluated in this study did not provide 
the same level of protection as was provided by Ingelvac® PRRS MLV. At this time, the 
costs for plasmid production, the practicality of the route of delivery, and the actual amount 
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of DNA vaccine material needed for dosage of large animals in a production setting are 
major drawbacks to the use of DNA vaccines. The goal is lofty for a PRRS DNA vaccine but 
if the number of SELI plasmids can be reduced and the concentration of the remaining 
relevant plasmids can be increased then sufficient protection may be achievable. Therefore, 
further vaccination/challenge studies with selected SELI fragments would serve as an 
effective tool in the delineation of the relevant immunogenic regions of the PRRS virus.  
While examining the tremendous body of work published on PRRSV protection 
strategies it was absolutely astonishing to find that so much has already been tested and 
learned about PRRSV since its classification, yet so little is truly known about protection 
from PRRSV. Simply put, PRRSV has been, is now, and will continue to be for at least the 
near future, one of the most significant and elusive pathogens researched in swine health. 
